Modulation of protein kinase C in antitumor treatment

  • J. Hofmann
Part of the Reviews of Physiology, Biochemistry and Pharmacology book series (REVIEWS, volume 142)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Accornero P, Radrizzani M, Care A, Mattia G, Chiodoni C, Kurrle R, Colombo MP (1998) HIV/gp 12 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas-L upregulation. FEBS Lett 436:467–465Google Scholar
  2. Acs P, Wang QJ, Bogi K, Marquez AM, Lorenzo PS, Biro T, Szallasi Z, Mushinski JF, Blumberg PM (1997) Both the catalytic and regulatory domains of protein kinase C chimeras modulate the proliferative properties of NIH 3T3 cells. J Biol Chem 272:28793–28799PubMedGoogle Scholar
  3. Adams LM, Dykes D, Harrison SD, Saleh J, Saah L (1993) Combined effect of the chemopotentiator SPC-100270, a protein kinase C (PKC) inhibitor, and doxorubicin (dox) or cisplatin (cis) on murine isografts and human tumor xenografts. Proc Am Assoc Cancer Res 34:410, 2448Google Scholar
  4. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland RC, Koi N, Fishel R, Howell SB (1996) Loss of DNA mismatch repair. in acquired resistance to cisplatin. Cancer Res 56:3087–3090PubMedGoogle Scholar
  5. Aftab DT, Yang JM, Hait WN (1994) Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res 6:59–70PubMedGoogle Scholar
  6. Ahmad S, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Glazer RI (1992) Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin. Mol Pharmacol 42:1004–1009PubMedGoogle Scholar
  7. Ahmad S, Glazer RI (1993) Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 43:858–862PubMedGoogle Scholar
  8. Ahmad S, Mineta T, Martuza RL, Glazer RI (1994) Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35:904–908PubMedGoogle Scholar
  9. Ahmed S, Lee J, Kozma R, Best A, Monfries C, Lim LA (1993) A novel functional target for tumor-promoting phorbol esters and lysophosphatidic acid. The p21rac-GTPase activating protein n-chimaerin. J Biol Chem 268:10709–10712PubMedGoogle Scholar
  10. Ahmed MM, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Wood DP Jr, Sells SF, Mohiuddin M, Rangnekar VM (1996) EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem 271:29231–29237PubMedGoogle Scholar
  11. Ahn CH, Kong JY, Choi WC, Wang MS (1996) Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells. Biochem Pharmacol 52:393–399PubMedGoogle Scholar
  12. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M (1991) Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51:4888–4892PubMedGoogle Scholar
  13. Akinaga S, Nomura K, Gomi K, Okabe M (1993) Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32:183–189PubMedGoogle Scholar
  14. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S (1997) G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57:1495–1501PubMedGoogle Scholar
  15. Alvaro V, Touraine P, Raisman Vozari R, Bai-Grenier F, Birman P, Joubert D (1992) Protein kinase C activity and expression in normal and adenomatous human pituitaries. Int J Cancer 50:724–730PubMedGoogle Scholar
  16. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B, Joubert D (1993) Invasive human pituitary tumors express a point-mutated alpha-protein kinase C. J Clin Endocrinol Metab 77:1125–1129PubMedGoogle Scholar
  17. Alvaro V, Prevostel C, Joubert D, Slosberg E, Weinstein IB (1997) Extopic expression of a mutant form of PKCalpha originally found in human tumors: aberrant subcellular translocation and effects on growth control. Oncogene 14:677–685PubMedGoogle Scholar
  18. Aquino A, Hartman KD, Knode MC, Grant S, Huang KP, Niu CH, Glazer RI (1988) Role of protein kinase C in phosphorylation of vinculin in adriamycin resistant HL 60 leukemia cells. Cancer Res 48:3324–3329PubMedGoogle Scholar
  19. Asada A, Zhao Y, Kondo S, Iwata M (1998) Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation. J Biol Chem 273:28392–28398PubMedGoogle Scholar
  20. Ask A, Persson L, Rehnholm A, Frostesjo L, Holm I, Heby O (1993) Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit. Cancer Res 53:5262–5268PubMedGoogle Scholar
  21. Assert R, Kruis W, Hardt M, Fischbach W, Schatz H, Pfeiffer A (1993) Expression of protein-kinase C (PKC)-a and b2 mRNA in normal mucosa, andomas and cell lines and growth arrest by PKC in differentiated colon T84 cells. Gastroenterology 89 (Suppl. 1), A2521Google Scholar
  22. Assert R, Kötter R, Bisping G, Scheppach W, Stahlnecker E, Müller KM, Dusel G, Schatz H, Pfeiffer A (1999) Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts: evidence for a less activated protein kinase C in small adenomas. Int J Cancer 80:47–53PubMedGoogle Scholar
  23. Azuma Y, Onishi Y, Sato Y, Kizaki H (1993) Induction of mouse thymocyte apoptosis by inhibitors of tyrosine kinases is assciated with dephosphorylation of nuclear proteins. Cell Immunol 152:271–278PubMedGoogle Scholar
  24. Azzi A, Boscoboinik D, Hensey C (1992) The protein kinase C and protein kinase C related gene families. Eur J Biochem 208:547–557PubMedGoogle Scholar
  25. Baltuch GH, Dooley NP, Couldwell WT, Yong VW (1993) Staurosporine differentially inhibits glioma versus non-glioma cell lines. J Neurooncol 16:141–147PubMedGoogle Scholar
  26. Baltuch GH, Dooley NP, Rostworowski KM, Villemure JG, Yong VW (1995) Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 24:241–250PubMedGoogle Scholar
  27. Bamberger AM, Bamberger CM, Wald M, Kratzmeier M, Schulte HM (1996) Protein kinase C (PKC) isoenzyme expression pattern as an indicator of proliferative activity in uterine tumor cells. Mol Cell Endocrinol 123:81–88PubMedGoogle Scholar
  28. Basu A, Teicher BA, Lazo JS (1990) Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 265:8451–8457PubMedGoogle Scholar
  29. Basu A (1993) The potential of protein kinase C as a target for anticancer treatment. Pharmac. Ther. 59:257–280Google Scholar
  30. Basu A, Cline JS (1995) Oncogenic transformation alters cisplatin induced apoptosis in rat embryo fibroblasts. Int J Cancer 63:597–603PubMedGoogle Scholar
  31. Basu A, Weixel KM (1995) Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and-resistant ovarian carcinoma cells. Int J Cancer 62:457–460PubMedGoogle Scholar
  32. Basu A, Weixel K, Saijo N (1996) Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and-resistant human small cell lung carcinoma cells. Cell Growth Differ 7:1507–1512PubMedGoogle Scholar
  33. Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT (1993) Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry. 32:9156–64PubMedGoogle Scholar
  34. Batlle E, Verdu J, Dominguez D, del Mont Llosas M, Diaz V, Loukili N, Paciucci R, Alameda F, de Herreros AG (1998) Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells. J Biol Chem 273:15091–15098PubMedGoogle Scholar
  35. Baxter G, Oto E, Daniel-Issakani S, Strulovici B (1992) Constitutive presens of a catalytic fragment of protein kinase Ce in a small cell lung carcinoma cell line. J Biol Chem 267:1910–1917PubMedGoogle Scholar
  36. Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V (1996) Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 10:426–433PubMedGoogle Scholar
  37. Beck J, Bohnet B, Brugger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C, Niethammer D, Gekeler V (1998) Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. Br J Cancer 77:87–91PubMedGoogle Scholar
  38. Begemann M, Kashimawo SA, Choi YJA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Gosh S, Fabbro D, Lampen NM (1996) Inhibition of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin Cancer Res 2: 1018–1030Google Scholar
  39. Bell SE, Quinn DM, Kellett GL, Warr JR (1998) 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Br J Cancer 78:1464–1470PubMedGoogle Scholar
  40. Beltran PJ, Fan D, Fidler IJ, O'Brian CA (1997) Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol 53:245–247PubMedGoogle Scholar
  41. Benzil DL, Finkelstein SD, Epstein MH, Finch PW (1992) Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res 52:2951–2956PubMedGoogle Scholar
  42. Berdel WE (1991) Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer 64:208–211PubMedGoogle Scholar
  43. Bergman PJ, Gravitt KR, Ward NE, Beltran P, Gupta KP, O'Brian CA (1997) Potent inuduction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanisms. Invest New Drugs 15:311–318PubMedGoogle Scholar
  44. Berkovic D, Berkovic K, Fleer EA, Eibl H, Unger C (1994) Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines. Eur J Cancer 30A:509–515PubMedGoogle Scholar
  45. Berkow RL, Kraft AS (1989) Bryostatin, a nonphorbol macrocyclic lactone activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 131:1109–1115Google Scholar
  46. Bernards R (1991) N-myc disrupts protein kinase C-mediated signal transduction in neuroblastoma. EMBO J 10:1119–1125PubMedGoogle Scholar
  47. Berra E, Diaz-Meco MT, Dominguez I, Municio MM, Sanz L, Lozano J, Chapkin RS, Moscat J (1993) Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell 74:555–563PubMedGoogle Scholar
  48. Berra E, Municio MM, Sanz L, Frutos S, Diaz-Meco MT, Moscat J (1997) Positioning atypical protein kinase C isoforms in the UV induced apoptotic signaling cascade. Mol Cell Biol 17:4346–4354PubMedGoogle Scholar
  49. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME (1993) High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82(10):3133–3140PubMedGoogle Scholar
  50. Blackburn RV, Galoforo SS, Berns CM, Motwani NM, Corry PM, Lee YJ (1998) Differential induction of cell death in human glioma cell lines by sodium nitroprusside. Cancer 82:1137–1145PubMedGoogle Scholar
  51. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130–135PubMedGoogle Scholar
  52. Blagosklonny MV (1999) A node between proliferation, apoptosis, and growth arrest. BioEssays 21:704–709PubMedGoogle Scholar
  53. Blake RA, Garcia-Paramio P, Parker PJ, Courtneidge SA (1999) Src promotes PKCδ degradation. Cell Growth Diff 10:231–241PubMedGoogle Scholar
  54. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P (1999) DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18:1723–1732PubMedGoogle Scholar
  55. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL, Hannun YA (1993) Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKCα. J Biol Chem 268:658–664PubMedGoogle Scholar
  56. Blobe GC, Obeid LM, Hannun YA (1994) Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13:411–431PubMedGoogle Scholar
  57. Blumberg PM (1991) Complexities of the protein kinase C pathway Mol Carcinog 4:339–344PubMedGoogle Scholar
  58. Borgatti P, Mazzoni M, Carini C, Neri LM, Marchisio M, Bertolaso L, Previati M, Zauli G, Capitani S (1996) Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation. Exp Cell Res 224:72–78PubMedGoogle Scholar
  59. Borner C, Wyss R, Regazzi R, Eppenberger U, Fabbro D (1987) Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer 40:344–348PubMedGoogle Scholar
  60. Borner C, Filipuzzi I, Weinstein IB, Imber R (1991) Failure of wild-type or a mutant form of protein kinase C-alpha to transform fibroblasts. Nature 353:78–80PubMedGoogle Scholar
  61. Brachwitz H, Vollgraf C (1995) Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther 66:39–82PubMedGoogle Scholar
  62. Brooks G, Wilson RE, Dooley TP, Goss MW, Hart IR (1991) Protein kinase C down-regulation, and not transient activation, correlates with melanocyte growth. Cancer Res 51:3281–3288PubMedGoogle Scholar
  63. Brown MJ, Wouters BG (1999) Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391–1399PubMedGoogle Scholar
  64. Buchner K (1995) Protein kinase C in the transduction of signals toward and within the cell nucleus. Eur J Biochem 228:211–221PubMedGoogle Scholar
  65. Budworth J, Davis R, Malkhandi J, Gant TW, Ferry DR, Gescher A (1996) Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer 73:1063–1068PubMedGoogle Scholar
  66. Budworth J, Gant TW, Gescher A (1997) Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Br J Cancer 75:1330–1335PubMedGoogle Scholar
  67. Bunch RT, Eastman A (1996) Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2:791–797PubMedGoogle Scholar
  68. Burger C, Wick M, Muller R (1994) Lineage-specific regulation of cell cycle gene expression in differentiating myeloid cells. J Cell Sci 107:2047–2054PubMedGoogle Scholar
  69. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, Pringle JF (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37:(Suppl III), 302–306Google Scholar
  70. Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB (1993) The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 8:2095–2104PubMedGoogle Scholar
  71. Cai H, Smola U, Wixler V, Eisenmann-Tappe I, Diaz-Meco MT, Moscat J, Rapp U, Cooper GM (1997) Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol 17:732–741PubMedGoogle Scholar
  72. Caloca MJ, Fernandez N, Lewin NE, Ching D, Modali R, Blumberg PM, Kazanietz MG (1997) Beta2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters. J Biol Chem 272:26488–26496PubMedGoogle Scholar
  73. Capiati DA, Limbozzi F, Tellez-Inon MT, Boland RL (1999) Evidence on the participation of protein kinase C alpha in the proliferation of cultured fibroblasts. J Cell Biochem 74:292–300PubMedGoogle Scholar
  74. Caravatti G, Meyer T, Fredenhagen A, Trinks U, Mett H, Fabbro D (1994) Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C. Bioorg Med Chem Lett 4:399–404Google Scholar
  75. Carey I, Noti JD (1999) Isolation of protein kinase C-alpha-regulated cDNAs associated with breast tumor aggressiveness by differential mRNA display. Int J Oncol 14:951–956PubMedGoogle Scholar
  76. Carnero A, Liyanage M, Stabel S, Lacal JC (1995) Evidence for different signalling pathways of PKC zeta and ras-p21 in Xenopus oocytes. Oncogene 11:1541–1547PubMedGoogle Scholar
  77. Cartee L, Kucera GL (1998) Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 41:403–412PubMedGoogle Scholar
  78. Cartee L, Kucera GL, Nixon JB (1998) The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells. Oncol Res 10:371–377PubMedGoogle Scholar
  79. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257:7847–7851PubMedGoogle Scholar
  80. Castro AF, Horton JK, Vanoye CG, Altenberg GA (1999) Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem Pharmacol 58:1723–1733PubMedGoogle Scholar
  81. Chakrabarty S, Huang S (1996) Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C alpha expression. J Exp Ther Oncol 1:218–221PubMedGoogle Scholar
  82. Chambers TC, McAvoy EM, Jacobs JW, Eilon G (1990a) Protein kinase C phosphorylates P-glycoprotein in multidrug-resistant human KB carcinoma cells. J Biol Chem 265:7679–7686PubMedGoogle Scholar
  83. Chambers TC, Chalikonda I, Eilon G (1990b) Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem Biophys Res Commun 169:253–259PubMedGoogle Scholar
  84. Chambers TC, Zheng B, Kuo JF (1992) Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 41:1008–1015PubMedGoogle Scholar
  85. Chambers TC, Pohl J, Raynor RL, Kuo JF (1993) Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem, 268:4592–4595PubMedGoogle Scholar
  86. Chambers TC, Pohl J, Glass DB, Kuo JF (1994) Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochem J 299:309–315PubMedGoogle Scholar
  87. Chaudhary PM, Roninson IB (1992) Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncology Research 4:281–290PubMedGoogle Scholar
  88. Chaudhary PM, Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:532–539Google Scholar
  89. Chauhan A, Chauhan VPS, Brockerhoff H, Wisniewski HM (1991) Action of amyloid beta-protein on protein kinase C activity. Life Sci 49:1555–1562PubMedGoogle Scholar
  90. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH (1998) The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 95:5287–5292PubMedGoogle Scholar
  91. Chen CY, Faller DV (1999) Selective inhibition of protein kinase C isoenzymes by Fas ligation. J Biol Chem 274:15320–15328PubMedGoogle Scholar
  92. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R (1999) BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59 (7 Suppl):1752s–1756sPubMedGoogle Scholar
  93. Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD, Chen DS (1998) Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 55:523–531PubMedGoogle Scholar
  94. Chida K, Kato N, Kuroki T (1986) Down regulation of phorbol diester receptors by proteolytic degradation of protein kinase C in a cultured cell line of fetal rat skin keratinocytes. J Biol Chem 261:13013–13018PubMedGoogle Scholar
  95. Chmura SJ, Nodzenski E, Weichselbaum RR, Quintans J (1996a) Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res 56:2711–2714PubMedGoogle Scholar
  96. Chmura SJ, Nodzenski E, Crane MA, Virudachalam S, Hallahan DE, Weichselbaum RR Quintans J (1996b) Cross-talk between ceramide and PKC activity in the control of apoptosis in WEHI-231. Adv Exp Med Biol 406:39–55PubMedGoogle Scholar
  97. Cho Y, Klein MG, Talmage DA (1998) Distinct functions of protein kinase Calpha and protein kinase Cbeta during retinoic acid-induced differentiation of F9 cells. Cell Growth Differ 9:147–154PubMedGoogle Scholar
  98. Choi PM, Tchou-Wong KM, Weinstein IB (1990) Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol 10:4650–4657PubMedGoogle Scholar
  99. Chu G (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269:787–790PubMedGoogle Scholar
  100. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW (1993) Biological and clinical implications of heat shock protein 27000 (Hsp27: a review. J Natl Cancer Inst 85:1558–1570PubMedGoogle Scholar
  101. Civoli F, Daniel LW (1998) Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines. Cancer Chemother Pharmacol 42:319–326PubMedGoogle Scholar
  102. Clavel M, Mauriac L, Vennin P, Namer M, Maugard-Louboutin C, Goupil A, Veyret C, Sindermann H, David M (1992) Topically applied miltefosine (hexadecylphosphocholine) in cutaneous relapses and/or skin metastasized breast cancer: a French multicentric study. Ann Oncol 3 (Suppl. 1): 65Google Scholar
  103. Cloud-Heflin BA, McMasters RA, Osborn MT, Chambers TC (1996) Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. Eur J Biochem 239:796–804PubMedGoogle Scholar
  104. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910PubMedGoogle Scholar
  105. Coppock DL, Buffolino P, Kopman C, Nathanson L (1995) Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. Exp Cell Res 221:92–102PubMedGoogle Scholar
  106. Cornford, P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS (1999) Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J. Pathol 154:137–144PubMedGoogle Scholar
  107. Couldwell WT, Antel JP, Apuzzo ML, Yong VW (1990) Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg 73:594–600PubMedGoogle Scholar
  108. Couldwell WT, Antel JP, Yong VW (1992) Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31:717–724PubMedGoogle Scholar
  109. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE (1994) Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345:43–46PubMedGoogle Scholar
  110. Courage C, Budworth J, Gescher A (1995) Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br J Cancer 71:697–704PubMedGoogle Scholar
  111. Courage C, Snowden R, Gescher A (1996) Differential effects of staurosporine analogs on cell cycle, growth and viability in A549 cells. Br J Cancer 74:1199–1205PubMedGoogle Scholar
  112. Courage C, Bradder SM, Jones T, Schultze-Mosgau MH, Gescher A (1997) Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine. Int J Cancer 73:763–768PubMedGoogle Scholar
  113. Craven PA, DeRubertis FR (1988) Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation by unsaturated fatty acids. Gastroenterology 95:676–85PubMedGoogle Scholar
  114. Craven PA, DeRubertis FR (1992) Alterations in protein kinase C in 1,2-dimethylhydrazine induced colonic carcinogenesis. Cancer Res 52:2216–2221PubMedGoogle Scholar
  115. Crespo P, Mischak H, Gutkind JS (1995) Overexpression of mammalian protein kinase C-zeta does not affect the growth characteristics of NIH 3T3 cells. Biochem Biophys Res Commun 213: 266–272PubMedGoogle Scholar
  116. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937PubMedGoogle Scholar
  117. Czendlik C, Graf P (1996) Safety, tolerability and pharmacokinetics of CGP 41251, a protein kinase C inhibitor (phase I study). Ann Oncol 7, Suppl 1: 264.Google Scholar
  118. Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43: 158–163PubMedGoogle Scholar
  119. Dale IL, Bradshaw TD, Gescher A, Pettit GR (1989) Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49:3242–3245PubMedGoogle Scholar
  120. Darbon JM, Valette A, Bayard F (1986) Phorbol esters inhibit the proliferation of MCF-7 cells. Possible implication of protein kinase C. Biochem Pharmacol 35:2683–2686PubMedGoogle Scholar
  121. Das KC, Guo X, White CW (1998) Protein kinase C°-dependent induction of Manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem 273:34639–34645PubMedGoogle Scholar
  122. Datta R, Kojima H, Yoshida K, Kufe D (1997) Caspase 3 mediated cleavage of protein kinase C theta in induction of apoptosis. J Biol Chem 272:20317–20320PubMedGoogle Scholar
  123. Davies R, Budworth J, Riley J, Snowden R, Gescher A, Gant TW (1996) Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Br J Cancer 73: 307–315PubMedGoogle Scholar
  124. Deacon EM, Pongracz J, Griffiths G, Lord JM (1997) Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. J Clin Pathol: Mol Pathol 50:124–131Google Scholar
  125. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res 56:3499–3507PubMedGoogle Scholar
  126. Defranco AL (1991) Immunosuppressants at work. Nature 352:754–755PubMedGoogle Scholar
  127. De las Alas MM, Aebi S, Fink D, Howell SB, Los G (1997) Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 89:1537–1541PubMedGoogle Scholar
  128. DeMaria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R (1997) Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science 277:1652–1655Google Scholar
  129. Denham DW, Franz MG, Denham W, Zervos EE, Gower WR Jr, Rosemurgy AS, Norman J (1998) Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 124: 218–224PubMedGoogle Scholar
  130. Denning MF, Wang Y, Nickoloff BJ, Wrone-Smith T (1998) Protein kinase cdelta is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J Biol Chem 273:29995–30002PubMedGoogle Scholar
  131. Dennis JU, Dean NM, Bennett CF, Griffith JW, Lang CM, Welch DR (1998) Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett 128:65–70PubMedGoogle Scholar
  132. Desrivieres S, Volarevic S, Mercep L, Ferrari S (1997) Evidence for different mechanisms of growth inhibition of T-cell lymphoma by phrobol esters and concanavalin A. J Biol Chem 272:2470–2476PubMedGoogle Scholar
  133. de Vente J, Kiley S, Garris T, Bryant W, Hooker J, Posekany K, Parker P, Cook P, Fletcher D, Ways DK (1995) Phorbol ester treatment of U937 cells with altered protein kinase C content and distribution induces cell death rather than differentiation. Cell Growth Differ 6:371–382PubMedGoogle Scholar
  134. Diaconu CC, Szathmari M, Keri G, Venetianer A (1999) Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer 80:1197–1203PubMedGoogle Scholar
  135. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J (1996) The product of par 4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86:777–786PubMedGoogle Scholar
  136. Dietel M, Arps H, Lage H, Niendorf A (1990) Membrane vesicle formation due to acquired mitoxanthrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50:6100–6106PubMedGoogle Scholar
  137. Dieter P, Fitzke E (1991) RO 31-8220 and RO 31-7549 show improved selectivity for PKC over staurosporine in macrophages. Biochem Biophys Res Commun 181:396–401PubMedGoogle Scholar
  138. Dive C, Hickman JA (1991) Drug-target interactions— only the first step in the commitment to a programmed cell-death. Br J Cancer 64:192–196.PubMedGoogle Scholar
  139. Doehmer J, Goeptar AR, Vermeulen NP (1993) Cytochromes P450 and drug resistance. Cytotechnology 12:357–366PubMedGoogle Scholar
  140. Dolci ED, Abramson R, Xuan Y, Siegfried J, Yuenger KA, Yassa DS, Tritton TR (1993) Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells. Int J. Cancer 54:302–308PubMedGoogle Scholar
  141. Dolfini E, Dasdia T, Perletti G, Romagnoni M, Piccinini F (1993) Analysis of calcium-dependent protein kinase-C isoenzymes in intrinsically resistant cloned lines of LoVo cells: reversal of resistance by kinase inhibitor 1-(5-isoquinolinylsulfonyl) 2-methylpiperazine. Anticancer-Res 13:1123–1127PubMedGoogle Scholar
  142. Dolfini E, Dasdia T, Arancia G, Molinari A, Calcabrini A, Scheper RJ, Flens MJ, Gariboldi MB, Monti E (1997) Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. Br J Cancer 76:67–76PubMedGoogle Scholar
  143. Dong, Z, Ward NE, Fan D, Gupta KP, O'Brian CA (1991) In vitro model for intrinsic drug resistance: effects of protein kinase C activators on chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 39:563–569PubMedGoogle Scholar
  144. Dooley NP, Baltuch GH, Groome N, Villemure JG, Yong VW (1998) Apoptosis is induced in glioma cells by antisense oligonucleotides to protein kinase C alpha and is enhanced by cycloheximide. Neuroreport 9:1727–1733PubMedGoogle Scholar
  145. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DG (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670PubMedGoogle Scholar
  146. Drew L, Groome N, Hallam TJ, Warr JR, Rumsby MG (1994) Changes in protein kinase C subspecies protein expression and activity in a series of multidrug-resistant human KB carcinoma cell lines. Oncol Res 6:429–438PubMedGoogle Scholar
  147. Drew L, Groome N, Warr JR, Rumsby MG (1996) Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx. Oncol Res 8:249–257PubMedGoogle Scholar
  148. Dwivedi RS, Wang LJ, Mirkin BL (1999) S-adenosylmethionine synthetase is overexpressed in murine neuroblastoma cells resistant to nucleoside analogue inhibitors of S-adenosylhomocysteine hydrolase: a novel mechanism of drug resistance. Cancer Res 56:1852–1856Google Scholar
  149. Efferth T, Volm M (1992) Expression of protein kinase C in human renal cell carcinoma cells with inherent resistance to doxorubicin Anticancer Res 12:2209–2211PubMedGoogle Scholar
  150. Eguchi Y, Srinivasan A, Tomaselli KJ, Shimizu S, Tsujimoto Y (1999) ATP-dependent steps in apoptotic signal transduction. Cancer Res 59:2174–2181PubMedGoogle Scholar
  151. Ek TP, Campbell MD, Deth RC, Gowraganahalli J (1989) Reduction of norepinephrine-induced tonic contraction and phosphoinositide turnover in arteries of spontaneously hypertensive rats. A possible role for protein kinase C. Am J Hypertens 2:40–45PubMedGoogle Scholar
  152. El-Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79–87PubMedGoogle Scholar
  153. Emanuel SL, Chamberlin HA, Cohen D (1999) Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells. Int J Oncol 14:487–494PubMedGoogle Scholar
  154. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, Kufe D (1995) Proteolytic activation of protein kinase C delta by an ICE like protease in apoptotic cells. EMBO J 14:6148–6156PubMedGoogle Scholar
  155. Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S (1991) Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 51:1613–1618PubMedGoogle Scholar
  156. Erickson LC (1991) The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition. Semin Cancer Biol 2:257–265PubMedGoogle Scholar
  157. Evans CA, Lord JM, Owen-Lynch PJ, Johnson G, Dive C, Whetton AD (1995) Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. J. Cell Sci 108:2591–2598PubMedGoogle Scholar
  158. Fabbro D, Regazzi R, Costa SD, Borner C, Eppenberger U (1986) Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells. Biochem Biophys Res Commun 1986 135:65–73Google Scholar
  159. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann, F, Ferrari S, Mett H, O'Reilly T, Meyer T (1999) Inhibitors of protein kinases: CGP 41251, a protein kinase C inhibitor with potential as an anticancer agent. Pharmacol Ther 82:293–301PubMedGoogle Scholar
  160. Fagerstrom S, Pahlman S, Gestblom C, Nanberg E (1996) Protein kinase C-epsilon is implicated in neurite outgrowth in differentiating human neuroblastoma cells. Cell Growth Differ 7:775–785PubMedGoogle Scholar
  161. Fan D, Fidler IJ, Ward NE, Seid C, Earnest LE, Housey GM, O'Brian CA (1992) Stable expression of a cDNA encoding rat brain protein kinase C-beta I confers a multidrug-resistant phenotype on rat fibroblasts. Anticancer Res 12:661–667PubMedGoogle Scholar
  162. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr, O'Connor PM (1997) Cells lacking CIP1/WAF1 genes exhibit preferential sensivity to cisplatin and nitrogen mustard. Oncogene 14:2127–2136PubMedGoogle Scholar
  163. Ferraris C, Cooklis M, Polakowska RR, Haake AR (1997) Induction of apoptosis through the PKC pathway in cultured dermal papilla fibroblasts. Exp Cell Res 234:37–46PubMedGoogle Scholar
  164. Farrow SN, Brown R (1996) New members of the Bcl-2 family and their protein partners. Curr Opin Gen Develop 6:45–49Google Scholar
  165. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659–668PubMedGoogle Scholar
  166. Findik D, Song Q, Hidaka H, Lavin M (1995) Protein kinase A inhibitors enhance radiation-induced apoptosis. J Cell Biochem 57:12–21PubMedGoogle Scholar
  167. Fine RL, Patel J, Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582–586PubMedGoogle Scholar
  168. Finkenzeller G, Marme D, Hug H (1992) Inducible overexpression of human protein kinase C in NIH 3T3 fibroblasts results in growth abnormalities. Cell Signall 4:163–177Google Scholar
  169. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78:539–542PubMedGoogle Scholar
  170. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivitry to mitomycin C and E09. J Natl Cancer Inst 88:259–269PubMedGoogle Scholar
  171. Forbes IJ, Zalewski PD, Giannakis C, Cowled PA (1992) Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester. Exp Cell Res 198:367–72PubMedGoogle Scholar
  172. Freemerman AJ, Turner AJ, Birrer MJ, Szabo E, Valerie K, Grant S (1996) Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C. Mol Pharmacol 49:788–795PubMedGoogle Scholar
  173. Freund A, Boos J, Harkin S, Schultze-Mosgau M, Veerman G, Peters GJ, Gescher A (1998) Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. Eur J Cancer 34:895–901PubMedGoogle Scholar
  174. Frutos S, Moscat J, Diaz-Meco MT (1999) Cleavage of zetaPKC but not lamda/iota PKC by caspase-3 during UV-induced apoptosis. J Biol Chem 274:10765–10770PubMedGoogle Scholar
  175. Fry DW, Jackson RC (1986) Mmebrane trnasport alterations as a mechanism of resistance to anticancer agents. Cancer Surv 5:47–79PubMedGoogle Scholar
  176. Fyfe D, Ferry DR, Smith A, de Takats P, Baker J, Kerr DJ (1996) Phase I clinical trial of the tyrosine kinase inhibitor quercetin combined with carboplatin in advanced cancer. Ann Oncology 7: Suppl. 1, 263Google Scholar
  177. Galski H, Lazarovici P, Gottesman MM, Murakata C, Matsuda Y, Hochman J (1995) KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells. Eur J Cancer 31A:380–388PubMedGoogle Scholar
  178. Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, Fuks Z, Kolesnick R (1998) 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 58:2260–2264PubMedGoogle Scholar
  179. Geiger T, Muller M, Dean NM, Fabbro D (1998) Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 13:35–45PubMedGoogle Scholar
  180. Geiges D, Marks F, Gschwendt M (1995) Loss of protein kinase Cδ from human HaCaT keratinocytes upon ras transfection is mediated by TGFα. Exp Cell Res 219:299–303PubMedGoogle Scholar
  181. Geilen CC, Haase R, Buchner K, Wieder T, Hucho F, Reutter W (1991) The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur J Cancer 27:1650–1653PubMedGoogle Scholar
  182. Gekeler V, Boer R, Überall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schächtele C, Klemm K, Grunicke H (1996) Effects of the selective bisindolyl-maleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 74:897–905PubMedGoogle Scholar
  183. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, Gottesman MM (1996) Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 217:1708–1716Google Scholar
  184. Gescher A (1992) Towards selective pharmacological modulation of protein kinase C-opportunities for the development of novel antineoplastic agents. Br J Cancer 66:10–19PubMedGoogle Scholar
  185. Gescher A (1998) Analogs of staurosporine: Potential anticancer drugs? Gen Pharmac 31:721–728Google Scholar
  186. Ghayur T, Hugunin M, Talanian RV, Ratnofsky S, Quinlan C, Emoto Y, Pandey P, Datta R, Huang Y, Kharbanda S, Allen H, Kamen R, Wong W, Kufe D (1996) Proteolytic activation of protein kinase C delta by an ICE/CED 3 like protease induces characteristics of apoptosis. J Exp Med 184:2399–2404PubMedGoogle Scholar
  187. Goekjian PG, Jirousek MR (1999) Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr Med Chem 6:877–903PubMedGoogle Scholar
  188. Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44:3643–3653PubMedGoogle Scholar
  189. Gollapudi S, Soni V, Thadepalli H, Gupta S (1995) Role of protein kinase beta isozyme in multidrug resistance in murine leukemia P388/ADR cells. J Chemother 7:157–159PubMedGoogle Scholar
  190. Goldstein DR, Cacace AM, Weinstein IB (1995) Overexpression of protein kinase C β1 in the SW480 colon cancer cell line causes growth suppression. Carcinogenesis 16:1121–1126PubMedGoogle Scholar
  191. Gomez J, de la Hera A, Silva A, Pitton C, Garcia A, Rebello A (1994) Implication of protein kinase C in IL-2-mediated proliferation and apoptosis in a murine T cell clone. Exp Cell Res 213:178–182PubMedGoogle Scholar
  192. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, Higgins CF (1996) Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271:13668–13674PubMedGoogle Scholar
  193. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedGoogle Scholar
  194. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS (1994) Rapid acqisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor aklylating agents. J Natl Cancer Inst 86:975–982PubMedGoogle Scholar
  195. Grant S, Turner A, Bartimole TM, Nelms P, Joe VC, Jarvis WD (1994) Modulation of 1-β-D-arabinofuranosylcytosine-induced apoptosis in human promyelocytic leukemia cells by staurosporine and other inhibitors of protein kinase C. Oncol Res 6:87–99PubMedGoogle Scholar
  196. Grant S, Jarvis DW (1996) Modulation of drug-induced apoptosis by interruption of protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 2:1915–1920PubMedGoogle Scholar
  197. Grant S, Turner AJ, Freemerman AJ, Wang Z, Kramer L, Jarvis WD (1996) Modulation of protein kinase C activity and calcium sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara C induced apoptosis. Exp Cell Res 228:65–75PubMedGoogle Scholar
  198. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD (1998) Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 4:611–618PubMedGoogle Scholar
  199. Gravitt KR, Ward NE, Fan D, Skibber JM, Levin B, O'Brian CA (1994) Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. Biochem Pharmacol 48:375–381PubMedGoogle Scholar
  200. Gray MO, Karliner JS, Mochly-Rosen D (1997) A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem 272:30945–30951PubMedGoogle Scholar
  201. Griffiths G, Garrone B, Deacon E, Owen P, Pongracz J, Mead G, Bradwell A, Watters D, Lord J (1996) The polyether bistratene A activates protein kinase C-delta and induces growth arrest in HL60 cells. Biochem Biophys Res Commun 222:802–808PubMedGoogle Scholar
  202. Gruber JR, Ohno S, and Niles RM (1992) Increased expression of protein kinase C alpha plays a key role in retinoic acid-induced melanoma differentiation. J Biol Chem 267:13356–13360PubMedGoogle Scholar
  203. Gschwendt M, Furstenberger G, Rose-John S, Rogers M, Kittstein W, Pettit GR, Herald CL, Marks F (1988) Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 9:555–562PubMedGoogle Scholar
  204. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199:93–98PubMedGoogle Scholar
  205. Gschwendt M (1999) Protein kinase Cδ. Eur J Biochem 259:555–564PubMedGoogle Scholar
  206. Guillem JG, O'Brian CA, Fitzer CJ, Forde KA, LoGerfo P, Treat M, Weinstein IB (1987) Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas. Cancer Res 47:2036–2039PubMedGoogle Scholar
  207. Gupta S, Patel K, Singh H, Gollapudi S (1994) Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 76:139–145PubMedGoogle Scholar
  208. Gupta KP, Ward NE, Gravitt KR, Bergman PJ, O'Brian CA (1996) Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 271:2102–2111PubMedGoogle Scholar
  209. Haggerty HG, Monroe JG (1994) A mutant of the WEHI-231 B lymphocyte line that is resistant to phorbol esters is still sensitive to antigen receptor-mediated growth inhibition. Cell Immunol 154:166–180PubMedGoogle Scholar
  210. Hagiwara M, Hachiya T, Watanabe M, Usuda N, Iida F, Tamai K, Hidaka H (1990) Assessment of protein kinase C isoenzymes by immunoassay and overexpression of type II in thyroid adenocarcinoma. Cancer Res 50:5515–5519PubMedGoogle Scholar
  211. Hähnel R, Gschwendt M (1995) The interaction between protein kinase C (PKC) and estrogens. Int J Oncol 7:11–16Google Scholar
  212. Haimovitz-Friedman A, Kann CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, Kolesnick RN (1994a) Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 180:525–535PubMedGoogle Scholar
  213. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaeli J, Vlodavsky I, Fuks Z (1994b) Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54:2591–2597PubMedGoogle Scholar
  214. Hait WN, DeRosa WT (1991) The role of the phorbol ester receptor/protein kinase C in the sensitivity of leukemic cells to anthracyclines. Cancer Commun 3:77–81PubMedGoogle Scholar
  215. Hallahan DE, Virudachalam S, Schwartz JL, Panje N, Mustafi R, Weichselbaum RR (1992) Inhibition of protein kinases sensitizes human tumor cells to ionizing radiation. Radiat Res 129:345–350PubMedGoogle Scholar
  216. Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W, Weinstein IB (1996) Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 7:699–710PubMedGoogle Scholar
  217. Hannun YA (1998) Functions of ceramide in coordinating cellular responses to stress. Science 274:1855–1859Google Scholar
  218. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda V, Higgins CF (1995) Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 14:68–75PubMedGoogle Scholar
  219. Harkin ST, Cohen GM, Gescher A (1998) Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Mol Pharmacol 54:663–670PubMedGoogle Scholar
  220. Hatada S, Sakanoue Y, Kusunoki M, Kobayashi A, Utsunomiya J (1992) Protein kinase C activity in human thyroid carcinoma and adenoma. Cancer 70:2918–2922PubMedGoogle Scholar
  221. Haq R, Zanke B (1998) Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev 17:233–239PubMedGoogle Scholar
  222. Heesbeen EC, Verdonck LF, Staal GE, Rijksen G (1994) Protein kinase C is not involved in the cytotoxic action of 1-octadecyl-2-O-methyl-sn-glycerol-3-phosphocholine in HL-60 and K562 cells. Biochem Pharmacol 47:1481–1488PubMedGoogle Scholar
  223. Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32:90–95PubMedGoogle Scholar
  224. Hirata J, Kikuchi Y, Kita T, Imaizumi E, Tode T, Ishii K, Kudoh K, Nagata I (1993) Modulation of sensitivity of human ovarian cancer cells to cisdiamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine. Int J Cancer 55:521–527PubMedGoogle Scholar
  225. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMedGoogle Scholar
  226. Hoelting T, Duh QY, Clark OH, Herfarth C (1996) Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C. Cancer Lett 100:89–93PubMedGoogle Scholar
  227. Hocevar BA, Fields AP (1991) Selective translocation of βII-PKC to the nucleus of human promyelocytic (HL-60) leukemia cells. J Biol Chem 266:28–33PubMedGoogle Scholar
  228. Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Überall F, Grunicke H (1988) Enhancement of the antiproliferative effect of cis diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382–388PubMedGoogle Scholar
  229. Hofmann J, Überall F, Posch L, Maly K, Herrmann DBJ, Grunicke H (1989) Synergistic enhancement of the anti proliferative activity of cis diamminedichloroplatinum(II) by the new ether lipid analogue BM 41 440, an inhibitor of protein kinase C. Lipids 24:312–317PubMedGoogle Scholar
  230. Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H (1990) Enhancement of the antiproliferative activity of cis diamminedichloroplatinum(II) by quercetin. Int J Cancer 45:536–539PubMedGoogle Scholar
  231. Hofmann J, Gekeler V, Ise W, Noller A, Mitterdorfer J, Hofer S, Utz I, Gotwald M, Boer R, Glossmann H, Grunicke H (1995) Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol 49:603–609PubMedGoogle Scholar
  232. Hofmann J, Utz I, Spitaler M, Hofer S, Rybczynska M, Beck WT, Herrmann DB, Grunicke H (1997) Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440). Br J Cancer 76:862–869PubMedGoogle Scholar
  233. Hofmann J (1997) The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 11:649–669PubMedGoogle Scholar
  234. Hofmann K, Dixit VM (1999) Reply to Kolesnick and Hannun, and Perry and Hannun. Trends Biochem Sci 282, 227Google Scholar
  235. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G (1999) Antifolate resistance mediated by multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532–2535PubMedGoogle Scholar
  236. Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101–107PubMedGoogle Scholar
  237. Housey GM, Johnson MD, Hsiao WL, O'Brian CA, Murphy JP, Kirschmeier P, Weinstein IB (1988) Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell 52:343–354PubMedGoogle Scholar
  238. Hsiao WL, Housey GM, Johnson MD, Weinstein IB (1989) Cells that overproduce protein kinase C are more susceptible to transformation by an activated. H-ras oncogene. Mol Cell Biol 9:2641–2647PubMedGoogle Scholar
  239. Hu H (1996) Recent discovery and development of selective protein kinase C inhibitors. Drug Discov Today 1:438–447Google Scholar
  240. Hu YP, Robert J (1997) Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance. J Cancer Res Clin Oncol 123:201–210PubMedGoogle Scholar
  241. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer-drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91:10394–10398PubMedGoogle Scholar
  242. Hug H, Sarre TF (1993) Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 291:329–343PubMedGoogle Scholar
  243. Hunakova L, Sulikova M, Duraj J, Sedlak J, Chorvath B (1996) Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors. Neoplasma 43:291–295PubMedGoogle Scholar
  244. Hundle B, McMahon T, Dadgar J, Messing RO (1995) Overexpression of epsilonprotein kinase C enhances nerve growth factor-induced phosphorylation of mitogen-activated protein kinases and neurite outgrowth. J Biol Chem 270:30134–30140PubMedGoogle Scholar
  245. Husain A, Yan XJ, Rosales N, Aghajanian C, Schwartz GK, Spriggs DR (1997) UCN-01 in Ovary Cancer Cells: Effective as a Single Agent and in Combination with cis-Diamminedichloroplatinum(II)Independent of p53 Status. Clin Cancer Res 3:2089–2097PubMedGoogle Scholar
  246. Husain A, He G, Venkatraman ES, Spriggs DR (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120–1123PubMedGoogle Scholar
  247. Ikegami Y, Yano S, Nakao K, Fujita F, Fujita M, Sakamoto Y, Murata N, Isowa K (1995) Antitumour activity of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on murine and human tumour models. Arzneim Forsch 45:1225–1230Google Scholar
  248. Ikegami Y, Yano S, Nakao K (1996a) Antitumour effect of CGP 41251, a new selective protein kinase C inhibitor on human non-small cell lung cancer cells. Jpn J Pharmac 70:65–72Google Scholar
  249. Ikegami Y, Yano S, Nakao K (1996b) Effects of the new selective kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneim.-Forsch 46:201–204Google Scholar
  250. Ilic D, Almeida EAC, Shlaepfer DD, Dazin P, Aizawa S, Damsky CH (1998) Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 143:547–560PubMedGoogle Scholar
  251. Imbra RJ, Karin M (1987) Metallothionein gene expression is regulated by serum factors and activators of protein kinase C. Mol Cell Biol 7:1358–1363PubMedGoogle Scholar
  252. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL (1992) Preferential elevation of protein kinase C isoform ßII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89:11059–11063PubMedGoogle Scholar
  253. Iseki R, Mukai M, Iwata M (1991) Regulation of T lymphocyte apoptosis. Signals for the antagonism between activation-and glucocorticoid-induced death. J Immunol 147:4286–4292PubMedGoogle Scholar
  254. Ishii HH, Gobe GC (1993) Epstein-Barr virus infection is associated with increased apoptosis in untreated and phorbol ester-treated human Burkitt's lymphoma (AW-Ramos) cells. Biochem Biophys Res Commun 192:1415–1423PubMedGoogle Scholar
  255. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKCß inhibitor. Science 272:728–731PubMedGoogle Scholar
  256. Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity to cis diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 265:3623–3627PubMedGoogle Scholar
  257. Isonishi S, Hom DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A, Howell SB (1991) Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51:5903–5909PubMedGoogle Scholar
  258. Issandou M, Bayard F, Darbon JM (1988) Inhibition of MCF-7 cell growth by 12-O-tetradecanoylphorbol-13-acetate and 1,2-dioctanoyl-sn-glycerol: distinct effects on protein kinase C activity. Cancer Res 48:6943–6950PubMedGoogle Scholar
  259. Issandou M, Darbon JM (1988) 1,2-Dioctanoyl-glycerol induces a discrete but transient translocation of protein kinase C as well as the inhibition of MCF-7 cell proliferation. Biochem Biophys Res Commun 151:458–465PubMedGoogle Scholar
  260. Iwata M, Iseki R, Sato K, Tozawa Y, Ohoka Y (1994) Involvement of protein kinase C epsilon in glucocorticoid induced apoptosis in thymocytes. Int Immunol 6:431–438PubMedGoogle Scholar
  261. Jamieson L, Carpenter L, Biden TJ, Fields AP (1999) Protein kinase Cl activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem 274:3927–3930PubMedGoogle Scholar
  262. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S (1994a) Induction of apoptotic DNA fragmentation and cell death in HL 60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54:1707–1714PubMedGoogle Scholar
  263. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S (1994b) Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1 [beta D arabinofuranosyl]cytosine induced apoptosis in HL 60 human promyelocytic leukemia cells. Biochem Pharmacol 47:839–852PubMedGoogle Scholar
  264. Jarvis WD, Fornari FA Jr, Tombes RM, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S (1998) Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 54:844–856PubMedGoogle Scholar
  265. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR (1995) A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72:461–468PubMedGoogle Scholar
  266. Jiang JB, Johnson MG, Defauw JM, Beine TM, Ballas LM, Janzen WP, Loomis CR, Seldin J, Cofield D, Adams L, Cianciolo G, Degen D, Vonhoff DD (1992) Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents. J Med Chem 35:4259–4263PubMedGoogle Scholar
  267. Jin L, Maeda T, Chandler WF, Lloyd RV (1993) Protein kinase C (PKC) activity and PKC messenger RNAs in human pituitary adenomas. Am J Pathol 142:569–578PubMedGoogle Scholar
  268. Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93:1075–1085PubMedGoogle Scholar
  269. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152–162PubMedGoogle Scholar
  270. Kahl-Rainer P, Karner-Hanusch J, Weiss W, Marian B (1994) Five of six protein kinase C isoenzymes present in normal mucosa show reduced protein levels during tumor development in the human colon. Carcinogenesis 15:779–782PubMedGoogle Scholar
  271. Kaina B, Lohrer H, Karin M, Herrlich P (1990) Overexpressed human metallothionein II gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sci USA 87:2710–2714PubMedGoogle Scholar
  272. Kakawami K, Futami H, Takahara J, Yamaguchi K (1996) UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 219:778–783Google Scholar
  273. Kampfer S, Hellbert K, Villunger A, Doppler W, Baier G, Grunicke HH, Überall F (1998) Transcriptional activation of c-fos by oncogenic Ha-Ras in mouse mammary epithelial cells requires the combined activities of PKC-λ, ɛ and ζ. EMBO J 17:4046–4055PubMedGoogle Scholar
  274. Kanter P, Leister KJ, Tomei LD, Wenner PA, Wenner CE (1984) Epidermal growth factor and tumor promoters prevent DNA fragmentation by different mechanisms. Biochem Biophys Res Commun 118:392–399PubMedGoogle Scholar
  275. Kariya K-I, Kawahara Y, Tsuda T (1987) Possible involvement of protein kinase C in platelet-derived growth factor-stimulated DNA synthesis in vascular smooth muscle cells. Atherosclerosis 83:251–255Google Scholar
  276. Keenan C, Thompson S, Knox K, Pears C (1999) Protein kinase C-alpha is essential for Ramos-BL B cell survival. Cell Immunol 196:104–109PubMedGoogle Scholar
  277. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Overexxpression of metallothionein confers resistance to anticancer drugs. Science 241:1815–1818Google Scholar
  278. Kelly ML, Tang Y, Rosensweig N, Clejan S, Beckman BS (1998) Granulocytemacrophage colony-stimulating factor rescues TF-1 leukemia cells from ionizing radiation-induced apoptosis through a pathway mediated by protein kinase Cα. Blood 92:416–424PubMedGoogle Scholar
  279. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS, Davidson NE (1992) Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52:1278–1283PubMedGoogle Scholar
  280. Kharbanda S, Datta R, Kufe D (1991) Regulation of c jun gene expression in HL 60 leukemia cells by 1 beta D arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism. Biochemistry 30:7947–7952PubMedGoogle Scholar
  281. Kieser A, Seitz T, Adler HS, Coffer P, Kremmer E, Crespo P, Gutkind JS, Henderson DW, Mushinski JF, Kolch W, Mischak H (1996) Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. Genes Dev 10:1455–1466PubMedGoogle Scholar
  282. Kiley SC, Clark KJ, Duddy SK, Welch DR, Jaken S (1999) Increased protein kinase Cδ in mammary tumor cells: relationship to transformation and metastatic progression. Oncogene 18:6748–6757PubMedGoogle Scholar
  283. Killion JJ, Beltran P, O'Brian CA, Yoon SS, Fan D, Wilson MR, Fidler IJ (1995) The antitumor activity of doxorubicin aganist drug-resistant murine carcinom is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Oncol Res 7:453–459PubMedGoogle Scholar
  284. Kim CY, Giaccia AJ, Strulovici B, Brown JM (1992) Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation. Br J Cancer 66:844–849PubMedGoogle Scholar
  285. Kim CH, Gollapudi S, Lee T, Gupta S (1997) Altered expression of the genes regulating apoptosis in multidrug resistant human myeloid leukemia cell lines overexpressing MDR1 or MRP gene. Int J Oncol 11:945–950Google Scholar
  286. Kinsella AR, Smith D, Pickard M (1997) Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75:935–945PubMedGoogle Scholar
  287. Kinter AL, Poli G, Maury W, Folks TM, Fauci AS (1990) Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol 64:4306–4312PubMedGoogle Scholar
  288. Kiss Z, Deli, E, Vogler WR, Kuo JF (1987) Antileukemic agent alkyllysophospholipid regulates phosphorylation of distinct proteins in HL60 and K562 cells and differentiation of HL60 cells promoted by phorbol ester. Biochem Biophys Res Commun 142:661–666PubMedGoogle Scholar
  289. Kizaki H, Tadakuma T, Odaka C, Muramatsu J, Ishimura Y (1989) Activation of a suicide process of thymocytes through DNA fragmentation by calcium ionophores and phorbol esters. J Immunol 143:1790–1794PubMedGoogle Scholar
  290. Klenner T, Engel J, Hilgard P (1998) Alkylphosphocholines: An update. Drugs of Today 34:Suppl. F, Prous Science 1–2Google Scholar
  291. Knox KA, Johnson GD, Gordon J (1993) A study of protein kinase C isozyme distribution in relation to Bcl-2 expression during apoptosis of epithelial cells in vivo. Exp Cell Res 207:68–73PubMedGoogle Scholar
  292. Knox KA, Gordon J (1994) Protein tyrosine kinases couple the surface immunoglobulin of germinal center B cells to phosphatidylinositol-dependent and-independent pathways of rescue from apoptosis. Cell Immunol 155:62–76PubMedGoogle Scholar
  293. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel R.S (1993) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci. USA 90:3294–3298PubMedGoogle Scholar
  294. Kobayashi D, Watanabe N, Yamauchi N, Tsuji N, Sato T, Sasaki H, Okamoto T, Niitsu Y (1997) Protein kinase C inhibitors augment tumor-necrosis-factor-induced apoptosis in normal human diploid cells. Chemotherapy 43:415–423PubMedGoogle Scholar
  295. Kolch W, Heidecker B, Kochs G, Hummel R, Vahidi M, Mischak H, Finkenzeller G, Marme D, Rapp UR (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249–252PubMedGoogle Scholar
  296. Kolesnick R, Hannun YA (1999) Ceramide and apoptosis. Trends Biochem Sci 282:224–225Google Scholar
  297. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J (1995a) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10:2001–2006PubMedGoogle Scholar
  298. Kondo Y, Woo ES, Michalska AE, Choo AKH, Lazo JS (1995b) Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 55:2021–2023PubMedGoogle Scholar
  299. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914–6919PubMedGoogle Scholar
  300. Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya S, Pugacheva EN, Rybalkina EY, Khokhlova OA, Chumakov PM (1995) Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts, Oncol Res 7:299–306PubMedGoogle Scholar
  301. Kopp R, Noelke B, Sauter G, Schildberg FW, Paumgartner G, Pfeiffer A (1991) Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 51:205–210PubMedGoogle Scholar
  302. Koriyma H, Kouchi Z, Umeda T, Saido TC, Momoi T, Ishiura S, Suzuki K (1999) Proteolytic activation of protein kinase C δ and ɛ by caspase-3 in U937 cells during chemotherapeutic agent-induced apoptosis. Cell Signal 11:831–838Google Scholar
  303. Koseki C, Herzlinger D, al-Awqati Q (1992) Apoptosis in metanephric development. J Cell Biol 119:1327–1333PubMedGoogle Scholar
  304. Kraft AS, Reeves JA, Askendel CL (1988) Differing modulation of PKC by bryostatin 1 and phorbol esters in JB6 mous epidermal cells. J Biol Chem 263:8437–8442PubMedGoogle Scholar
  305. Kusunoki M, Sakanoue Y, Hatada T, Yamamura T, Utsunomiya J (1992) Protein kinase C activity in human colonic adenoma and colorectal carcinoma. Cancer 69:24–30PubMedGoogle Scholar
  306. Kwiatkowska-Patzer B, Domanska-Janik K (1991) Increased 19 kDa protein phosphorylation and protein kinase C activity in pressure-overload cardiac hypertrophy. Basic Res Cardiol 86:402–409PubMedGoogle Scholar
  307. Lallena MJ, Diaz-Meco MT, Bren G, Paya CV, Moscat J (1999) Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol 19:2180–2188PubMedGoogle Scholar
  308. La Porta CA, Tessitore L, Comolli R (1997) Changes in protein kinase C alpha, delta and in nuclear beta isoform expression in tumour and lung metastatic nodules induced by diethylnitrosamine in the rat. Carcinogenesis 4:715–719Google Scholar
  309. La Porta CAM, Dolfini E, Comolli R (1998) Inhibition of protein kinase C-α isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cellst to doxorubicin exposure. Br J Cancer 78:1283–1287PubMedGoogle Scholar
  310. Laouar A, Glesne D, Huberman E (1999) Involvement of protein kinase C-beta and ceramide in tumor necrosis factor-alpha-induced but not Fas-induced apoptosis of human myeloid leukemia cells. J Biol Chem 274:23526–23534PubMedGoogle Scholar
  311. Laredo J, Huynh A, Muller C, Jaffrezou JP, Bailly JD, Cassar G, Laurent G, Demur C (1994) Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood 84:229–237PubMedGoogle Scholar
  312. Larocca LM, Teofili L, Sica S, Piantelli M, Maggiano N, Leone G, Ranelletti FO (1995) Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-beta 1 in these cells. Blood 85:3654–3661PubMedGoogle Scholar
  313. Lavie Y, Cao HAT, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272:1682–1687PubMedGoogle Scholar
  314. Lavie Y, Zhang ZC, Cao H-T, Han T-Y, Johnes RC, Liu YY, Jarman M, hardcastle IR, Giuliano AE, Cabot MC (1998) Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 77:928–932PubMedGoogle Scholar
  315. Lavin MF, Watters D, Song Q (1996) Role of protein kinase activity in apoptosis. Experientia 52:979–994PubMedGoogle Scholar
  316. Leach KL, James ML, Blumberg PM (1983) Characterization of a specific phorbol ester aporeceptor in moujse brain cytosol. Proc Natl Acad Sci USA 80:4208–4212PubMedGoogle Scholar
  317. Lee SA, Karaszkiewicz JW, Anderson WB (1992) Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 52:3750–3759PubMedGoogle Scholar
  318. Lee JY, Hannun YA, Obeid LM (1996a) Ceramide inactivates cellular protein kinase C alpha. J Biol Chem 271:13169–13174PubMedGoogle Scholar
  319. Lee HW, Smith L, Pettit GR, Bingham-Smith J (1996b) Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin. Am J Physiol 271(1 Pt 1):C304–311PubMedGoogle Scholar
  320. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, Tarakhovsky A (1996) Immunodeficiency in protein kinase Cbeta-deficient mice. Science 273:788–791PubMedGoogle Scholar
  321. Leszczynski D, Joenvaara S, Foegh ML (1995) Apoptosis of rat vascular smooth muscle cells is regulated by δ and ζ but not by α and ɛ isozymes of protein kinase C. Mol Biol Cell 6, Suppl:246aGoogle Scholar
  322. Leszczynski D, Joenvaara S, Foegh ML (1996) Protein kinase C alpha regulates proliferation but not apoptosis in rat coronary vascular smooth muscle cells. Life Sci 58:599–606PubMedGoogle Scholar
  323. Levin DE, Fields FO, Kunisawa R, Bishop JM, Thorner J (1990) A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle. Cell 62:213–224PubMedGoogle Scholar
  324. Levin D, Bartrett-Heubusch E (1992) Mutants in the S cerevisiae PKC1 gene display a cell cycle-specific osmotic stability defect. J Cell Biol 116:1079–1088Google Scholar
  325. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331PubMedGoogle Scholar
  326. Levy MF, Pocsidio J, Guillem JG, Forde K, LoGerfo P, Weinstein IB (1993) Decreased levels of protein kinase C enzyme activity and protein kinase C mRNA in primary colon tumors. Dis Colon Rectum 36:913–921PubMedGoogle Scholar
  327. Li H, Zhao L, Yang Z, Funder JW, Liu JP (1998) Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J Biol Chem 273:33436–33442PubMedGoogle Scholar
  328. Liu YY, Han TY, Giuliano AE, Cabo MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274:1140–1146PubMedGoogle Scholar
  329. Livneh E, Fishman DD (1997) Linking protein kinase C to cell-cycle control. Eur J Biochem 248:1–9PubMedGoogle Scholar
  330. Lotem J, Cragoe EJ Jr, Sachs L (1991) Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 78:953–960PubMedGoogle Scholar
  331. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967PubMedGoogle Scholar
  332. Lozano J, Berra E, Municio MM, Diaz-Meco MT, Dominguez I, Sanz L, Moscat J (1994) Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 269:19200–19202PubMedGoogle Scholar
  333. Lucas M, Sanchez-Margalet V, Sanz A, Solano F (1994) Protein kinase C activation promotes cell survival in mature lymphocytes prone to apoptosis. Biochem Pharmacol 47:667–672PubMedGoogle Scholar
  334. Lucas M, Sanchez Margalet V (1995) Protein kinase C involvement in apoptosis. Gen Pharmacol 26:881–887PubMedGoogle Scholar
  335. Lush RM, Dsenderowicz A, Figg WD, Headlee D, Inoue K, Sausville EA (1997) Surprising pharmacokinetics of UCN-01 in patients with refractory neoplasms may be due to high degree of plasma protein binding. Proc Am Assoc Cancer Res 38:600Google Scholar
  336. Ma LD, Marquardt D, Takemoto L., Center MS (1991) Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 266:5593–5599PubMedGoogle Scholar
  337. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JHM (1998a) Abrogated energydependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother Pharmacol 41:186–192PubMedGoogle Scholar
  338. Ma J, Maliepard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JHM (1998b) Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 77:1645–1652PubMedGoogle Scholar
  339. MacFarlane DE, O'Donnell PS (1993) Phorbol ester induces apoptosis in HL-60 promyelocytic leukemia cells but not in HL-60 PET mutant. Leukemia 7:1846–1851PubMedGoogle Scholar
  340. MacFarlane DE, Manzel L (1994) Activation of beta-isozyme of protein kinase C (PKC beta) is necessary and sufficient for phorbol ester-induced differentiation of HL-60 promyelocytes. Studies with PKC beta-defective PET mutant. J Biol Chem 269:4327–4331PubMedGoogle Scholar
  341. Magnelli L, Chiarugi V (1997) Regulation of p53 by protein kinase C during multistage carcinogenesis. J. Cancer Res Clin Oncol 123:365–369PubMedGoogle Scholar
  342. Mailhos C, Howard MK, Latchman DS (1994) A common pathway mediates retinoic acid and TPA dependent programmed cell death (apoptosis) of neuronal cells. Brain Res 644:7–12PubMedGoogle Scholar
  343. Manni A, Buckwalter E, Etindi R, Kunselman S, Rossini A, Mauger D, Dabbs D, Demers L (1996) Induction of a less aggressive breast cancer phenotype by protein kinase C-α and-β overexpression. Cell Growth Diff 7:1187–1198PubMedGoogle Scholar
  344. Mansat V, Laurent G, Levade T, Bettaieb A, Jaffrezou JP (1997) The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res 57:5300–5304PubMedGoogle Scholar
  345. Marte B, Meyer T, Stabel S, Standke GJ, Jaken S, Fabbro D, Hynes NE (1994) Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression. Cell Growth Differ 5:239–247PubMedGoogle Scholar
  346. Martelli AM, Sang N, Borgatti P, Capitani S, Neri LM (1999) Multiple biological responses activated by nuclear protein kinase C. J Cell Biochem 74:499–521PubMedGoogle Scholar
  347. Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ (1999) pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 57:1037–1046PubMedGoogle Scholar
  348. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, Schachtele C (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268:9194–9197PubMedGoogle Scholar
  349. Masanek U, Stammler G, Volm M (1997) Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs 8:189–198PubMedGoogle Scholar
  350. Masumoto N, Nakano S, Jujishima H, Hohno K, Niho Y (1999) v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 80:731–737PubMedGoogle Scholar
  351. Mathias S, Pena LA, Kolesnick RN (1998) Signal transduction of stress via ceramide. Biochem J 335 (Pt 3):465–480PubMedGoogle Scholar
  352. Matsumoto T, Tani E, Yamaura I, Miyaji K, Kaba K (1995) Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 36:565–571PubMedGoogle Scholar
  353. Mattern J, Eichhorn U, Kaina B, Volm M (1998) O6-Methylguanine-DNA methyltransferase activity and sensitivity to cyclophoshamide and cisplatin in human lung tumor xenografts. Int. J Cancer 77:919–922PubMedGoogle Scholar
  354. Mayne GC, Murray AW (1998) Evidence that protein kinase Cε mediates phorbol ester inhibition of calphostin C-and tumor necrosis factor-α-induced apoptosis in U937 histiocytic lymphoma cells. J Biol Chem 273:24115–23121PubMedGoogle Scholar
  355. McBain JA, Pettit GR, Mueller GC (1990) Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation. Cell Growth Differ 1:281–291PubMedGoogle Scholar
  356. McConkey DJ, Hartzell P, Jondal M, Orrenius S (1989) Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that simulate protein kinase C. J Biol Chem 264:13399–13402PubMedGoogle Scholar
  357. McConkey DJ, Nicotera P, Orrenius S (1994) Signalling and chromatin fragmentation in thymocyte apoptosis. Immunol Rev 142:343–363PubMedGoogle Scholar
  358. McCoy C, Smith DE, Cornwell MM (1995) 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol Cell Biol 15:6100–6108PubMedGoogle Scholar
  359. McCoy C, McGee SB, Cornwell MM (1999) The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ 10:377–386PubMedGoogle Scholar
  360. McDonald III ER, Wu GS, Waldman T, El-Deiry WS (1996) Repair Defect in p21 WAF1/CIP1_-/-human cancer cells. Cancer Res 56:2250–2255PubMedGoogle Scholar
  361. McDonald AC, Propper D, King D, Champain K, Graf P, Man A, Caponigro F, Thavasu P, Balkwill F, Twelves C, Kaye SB (1997) Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase C. Proc Am Soc Clin Oncol 16:742Google Scholar
  362. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179–1187PubMedGoogle Scholar
  363. Meggio F, Donella Deana A, Ruzzene M, Brunati AM, Cesaro L, Guerra B, Meyer T, Mett H, Fabbro D, Furet P, Dobrowolska A, Pinna LA (1995) Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for resistance of protein kinase CK2. Eur J Biochem 234:317–322PubMedGoogle Scholar
  364. Megidish T, Mazurek N (1989) A mutant protein kinase C that can transform fibroblasts. Nature 342:807–811PubMedGoogle Scholar
  365. Mehta AB, Virchis AE, Jones DT, Hart SM, Wickremasinghe RG, Prentice HG, Young KL, Man A, Csermak-Renner K, Ganeshaguru K (1997) Preliminary results of a phase 2 study on protein kinase C inhibitor (CGP 41251) in low grade lymphoproliferative disorders. Blood 90 (Suppl. 1):3646Google Scholar
  366. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332:281–292PubMedGoogle Scholar
  367. Merrit JE, Sullivan JA, Drew L, Khan A, Wilson K, Mulqueen M, Harris W, Bradshaw D, Hill CH, Rumsby M, Warr R (1999) The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells. Cancer Chemother Pharmacol 43:371–378Google Scholar
  368. Meyer T, Regenass U, Fabbro D, Alteri E, Rösel J, Müller M, Carvatti G, Matter A (1989) A derivative of staurosporine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative as well as in vivo antitumor activity. Int J Cancer, 43:851–856PubMedGoogle Scholar
  369. Migliorati G, Nicoletti I, D'Adamio F, Spreca A, Pagliacci C, Riccardi C (1994) Dexamethasone induces apoptosis in mouse natural killer cells and cytotoxic T lymphocytes. Immunology 81:21–26PubMedGoogle Scholar
  370. Militante JD, Lombardini JB (1999) Taurine uptake activity in the rat retina: protein kinase C-independent inhibition by chelerythrine. Brain Res 818:368–374PubMedGoogle Scholar
  371. Miller DS, Sussman CR, Refro JL (1998) Protein kinase C regulation of P-glycoprotein-mediated xenobiotic secretion in renal proximal tubule. Am J Physiol 275:F785–795PubMedGoogle Scholar
  372. Mischak H, Goodnight JA, Kölch W, Martiny-Baron G, Schaechtele C, Kazanietz MG, Blumberg PM, Pierce JH, Mushinski JF (1993) Overexpression of protein kinase C-delta and_-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 268:6090–6096PubMedGoogle Scholar
  373. Mishima K, Ohno S, Shitara N, Yamaoka K, Suzuki K (1994) Opposite effects of the overexpression of protein kinase C gamma and delta on the growth properties of human glioma cell line U251 MG. Biochem Biophys Res Commun 201:363–372PubMedGoogle Scholar
  374. Misra-Press A, Fields AP, Samols D, Goldthwait DA (1992) Protein kinase C isoforms in human glioblastoma cells. Glia 6:188–197PubMedGoogle Scholar
  375. Miyamoto K, Wakusawa S, Inoko K, Takagi K, Koyama M (1992) Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells. Cancer-Lett 64:177–183PubMedGoogle Scholar
  376. Miyamoto K, Inoko K, Wakusawa S, Kajita S, Hasegawa T, Takagi K, Masao K (1993) Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo. Cancer Res 53:1555–1559PubMedGoogle Scholar
  377. Mizuno K, Noda K, Ueda Y, Hanaki H, Saido TC, Ikuta T, Kuroki T, Tamaoki T, Hirai S, Osada S, Ohno S (1995) UCN-01, an antitumor drug, is a selective inhibitor of the conventional PKC subfamily FEBS Lett 359:259–261PubMedGoogle Scholar
  378. Mochley-Rosen D, Gordon AS (1998) Anchoring proteins for protein kinase C: a means for isoenzyme selectivity. FASEB J 12:35–42Google Scholar
  379. Montaner S, Ramos A, Perona R, Esteve P, Carnero A, Lacal JC (1995) Overexpression of PKC zeta in NIH3T3 cells does not induce cell transformation nor tumorigenicity and does not alter NF kappa B activity. Oncogene 10:2213–2220PubMedGoogle Scholar
  380. Moore NC, Jenkinson EJ, Owen JJ (1992) Effects of the thymic microenvironment on the response of thymocytes to stimulation. Eur J Immunol 22:2533–2537PubMedGoogle Scholar
  381. Moreland NJ, Illand M, Kim YT, Paul J, Brown R (1999) Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res 59:2102–2106PubMedGoogle Scholar
  382. Morgan PF, Fine RL, Montgomery P, Marangos PJ (1991) Multidrug resistance in MCF-7 human breast cancer cells is associated with increased expression of nucleoside transporters and altered uptake of adenosine. Cancer Chemother Pharmacol 29:127–132PubMedGoogle Scholar
  383. Morris CM, Smith GJ (1992) Altered levels and protein kinase C-mediated phosphorylation of substrates in normal and transformed mouse lung epithelial cells. Exp Cell Res 200:149–155PubMedGoogle Scholar
  384. Morse-Gaudio M, Connolly JM, Rose DP (1998) Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int J Oncol 12:1349–1354PubMedGoogle Scholar
  385. Moscow JA (1998) Methotrexate transport and resistance. Leuk Lymphoma 30:215–224PubMedGoogle Scholar
  386. Motyka B, Griebel PJ, Reynolds JD (1993) Agents that activate protein kinase C rescue sheep ileal Peyer's patch B cells from apoptosis. Eur J Immunol 23:1314–1321PubMedGoogle Scholar
  387. Muller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K (1995) PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14:1961–1969PubMedGoogle Scholar
  388. Murray NR, Baumgardner GP, Burns DJ, Fields AP (1993) Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation. J Biol Chem 268:15847–15853PubMedGoogle Scholar
  389. Murray NR, Fields AP (1997) Atypical protein kinase C ι protects human leukemia cells against drug-induced apoptosis. J Biol Chem 272:27521–27524PubMedGoogle Scholar
  390. Murray NR, Thompson LJ, Fields AP (1997) The role of protein kinase C in cellular proliferation and cell cycle control. In: Molecular Biology Intelligence Unit: Protein. Kinase C, PJ Parker and LV Dekker (eds.), R.G. Landes Company, Austin, TX, Springer-Verlag, Heidelberg, 97–120Google Scholar
  391. Nakamura S, Wakusawa S, Tajima K, Miyamoto K, Hagiwara M, Hidaka H (1991) Effects of isoquinolinesulphonamide compounds on multidrug-resistant P388 cells. J Pharm Pharmacol 45:268–273Google Scholar
  392. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide ot protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17:3586–3595PubMedGoogle Scholar
  393. Newton AC, Johnson JE (1998) Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1376:155–172PubMedGoogle Scholar
  394. Ng T, Squire A, Hansra G, Bornancin F, Prevostel C, Hanby A, Harris W, Barnes D, Schmidt S, Mellor H, Bastiaens PI, Parker PJ (1999) Imaging protein kinase Calpha activation in cells. Science 283:2085–2089PubMedGoogle Scholar
  395. Niedel JE, Kuhn L, Vandenbark GR (1983) Phorbol diester receptor copurifies with protein kinase C. Proc Natl Acad Sci USA 80:36–40PubMedGoogle Scholar
  396. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Tershima Y, Shibuya M, Terada M, Saijo N (1991) Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Int J Cancer 63:237–241Google Scholar
  397. Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484–496PubMedGoogle Scholar
  398. Nixon JS (1997) The biology of protein kinase C inhibitors. In: Molecular Biology Intelligence Unit: Protein Kinase C, PJ Parker and LV Dekker (eds.), R.G. Landes Company, Austin, TX, Springer-Verlag, Heidelberg, 205–236Google Scholar
  399. Noe V, Ciudad CJ (1995) Protein kinase C inhibitors reduce phorbol ester-induced resistance to methotrexate in Chines hamster ovary cells. Biochem Pharmacol 50:337–346PubMedGoogle Scholar
  400. Noseda A, Berens ME, White JG, Modest EJ (1988) In vitro antiproliferative activity of combinations of ether lipid analogues and DNA interactive agents against human tumor cells. Cancer Res 48:1788–1791PubMedGoogle Scholar
  401. Obeid LM, Linardic CM, Karolak LA, Hannun YA (1993) Programmed cell death induced by ceramide. Science 259:1769–1771PubMedGoogle Scholar
  402. O'Brian CA, Vogel, VG, Singletary SE, Ward NE (1989a) Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49:3215–3217PubMedGoogle Scholar
  403. O'Brian CA, Fan D, Ward NE, Seid C, Fidler IJ (1989b) Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett 246:78–82PubMedGoogle Scholar
  404. O'Brian CA, Fan D, Ward NE, Dong Z, Iwamoto L, Gupta KP, Earnest LE, Fidler IJ (1991a) Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. Biochem Pharmacol Mar 1;41(5):797–806Google Scholar
  405. O'Brian CA, Ward NE, Liskamp RM, de-Bont DB, Earnest LE, van Boom JH, Fan D (1991b) A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycin. Invest New Drugs 9:169–179PubMedGoogle Scholar
  406. O'Brian CA, Ward NE, Gravitt KR, Gupta KP (1995) The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. Prog Clin Biol Res 391:117–120PubMedGoogle Scholar
  407. Ochs K, Sobol RW, Wilson SH, Kaina B (1999) Cells deficient in DNA polymerase beta are hypersensitive to alkylating agent-induced apoptosis and chromosomal breakage. Cancer Res 59:1544–1551PubMedGoogle Scholar
  408. O'Driscoll KR, Madden PV, Christiansen KM, Viage A, Slaga TJ, Fabbro D, Powell CT, Weinstein IB (1994) Overexpression of protein kinase C beta I in a murine keratinocyte cell line produces effects on cellular growth, morphology and differentiation. Cancer Lett 83:249–259PubMedGoogle Scholar
  409. O'Driscoll KR, Teng KK, Fabbro D, Greene LA, Weinstein IB (1995) Selective translocation of protein kinase C-delta in PC12 cells during nerve growth factor-induced neuritogenesis. Mol Biol Cell 6:449–458PubMedGoogle Scholar
  410. Ohmi Y, Ohta A, Sasakura Y, Sato N, Yahata T, Santa K, Habu S, Nishimura T (1997) The role of phorbol ester-sensitive protein kinase C isoforms in lymphokine-activated killer cell-mediated cytotoxicity: dissociation between perforin-dependent and Fas-dependent cytotoxicity. Biochem Biophys Res Commun 235:461–464PubMedGoogle Scholar
  411. Ohmichi M, Zhu G, Saltiel AR (1993) Nerve growth factor activates calcium-insensitive protein kinase C-epsilon in PC-12 rat pheochromocytoma cells. Biochem J 295 (Pt 3):767–772PubMedGoogle Scholar
  412. Ohmori T, Arteaga CL (1998) Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity. Cell Growth Differ 9:345–353PubMedGoogle Scholar
  413. Ojeda F, Guarda MI, Maldonado C, Folch H, Diehl H (1992) Role of protein kinase-C in thymocyte apoptosis induced by irradiation. Int J Radiat Biol 61:663–667PubMedGoogle Scholar
  414. Oka M, Ogita K, Ando H, Horikawa T, Hayashibe K, Saito N, Kikkawa U, Ichihashi M (1996) Deletion of specific protein kinase C subspecies in human melanoma cells. J Cell Physiol 167:406–412PubMedGoogle Scholar
  415. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, Takahashi Y, Masuma R (1977) A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot 30:275–282PubMedGoogle Scholar
  416. Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC (1990) The role of glutathione in drug resistance. Cancer Treat Rev 17A:45–50Google Scholar
  417. Perego P, Casati G, Gambetta RA, Soranzo C, Zunino F (1993) Effect of modulation of protein kinase C activity on cisplatin toxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells. Cancer Lett, 72:53–58PubMedGoogle Scholar
  418. Perez RP, Hamilton TC, Ozols RF (1990) Resistance to alkylating agents and cis-platin: insights from ovarian carcinoma model systems. Pharmac Ther 48:19–27Google Scholar
  419. Perletti GP, Folini M, Lin HC, Mischak H, Piccinini F, Tashjian AH Jr (1996) Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. Oncogene 12:847–854PubMedGoogle Scholar
  420. Perletti GP, Marras E, Concari P, Piccinini F, Tshjian AH Jr (1999) PKC delta acts as a growth and tumor suppressor in rat colonic epithelial cells. Oncogene 18:1251–1256PubMedGoogle Scholar
  421. Perotti M, Toddei F, Mirabelli F, Vairetti M, Bellomo G, McConkey DJ, Orrenius S (1990) Calcium-dependent DNA fragmentation in human synovial cells exposed to cold shock. FEBS Lett 259:331–334PubMedGoogle Scholar
  422. Persons DA, Wilkinson, WO, Bell RM, Finn OJ (1988) Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA. Cell 52:447–458PubMedGoogle Scholar
  423. Pettit GR, Day JF, Hartwell JL, Wood HB (1970) Antineoplastic components of marine animals. Nature 227:962–963PubMedGoogle Scholar
  424. Phan SC, Morotomi M, Guillem JG, LoGerfo P, Weinstein IB (1991) Decreased levels of 1,2-sn-diacylglycerol in human colon tumors. Cancer Res 51:1571–1573PubMedGoogle Scholar
  425. Piovesan B, Pennell N, Berinstein NL (1998) Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Oncogene 17:2339–2350PubMedGoogle Scholar
  426. Pizao PE, Peters GJ, Van Ark-Otte J, Smets LA, Smitskamp-Wilms E, Winograd B, Pinedo HM, Giaccone G (1993) Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. Eur J Cancer 29A:1566–1573PubMedGoogle Scholar
  427. Pollak IF, Kawecki S, Lazo JS (1996) Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cis-platin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 84:1024–1032Google Scholar
  428. Pongracz J, Clark P, Neoptolemous JP, Lord JM (1995a) Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 61:35–39PubMedGoogle Scholar
  429. Pongracz J, Tuffley W, Johnson GD, Deacon EM, Burnett D, Stockley RA, Lord JM (1995b) Changes in protein kinase C isoenzyme expression associated with apoptosis in U937 myelomonocytic cells. Exp Cell Res 218:430–438PubMedGoogle Scholar
  430. Pongracz J, Deacon EM, Johnson GD, Burnett D, Lord JM (1996) Doppa induces cell death but not differentiation of U937 cells: evidence for the involvement of PKC-beta 1 in the regulation of apoptosis. Leuk Res 20:319–326PubMedGoogle Scholar
  431. Posada J, Vichi P, Tritton TR (1989a) Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res 49:6634–6639PubMedGoogle Scholar
  432. Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S, Tritton TR (1989b) Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. Cancer Commun 1:285–292PubMedGoogle Scholar
  433. Powell CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR (1996) Persistent membrane translocation of protein kinase C alpha during 120 tetradecanoylphorbol 13 acetate induced apopotosis of LNCaP human prostate cancer cells. Cell Growth Differ 7:419–428PubMedGoogle Scholar
  434. Powis G (1991) Signalling targets for anticancer drug development. Trends Pharmacol Sci 12:188–194PubMedGoogle Scholar
  435. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR (1993) A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:418–424PubMedGoogle Scholar
  436. Prendiville J, McGown AT, Gescher A, Dickson AJ, Courage C, Pettit GR, Crowther D, Fox BW (1994) Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1. Br J Cancer 70:573–578PubMedGoogle Scholar
  437. Prevostel C, Alvaro V, de-Boisvilliers F, Martin A, Jaffiol C, Joubert D (1995) The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene 11:669–674PubMedGoogle Scholar
  438. Prevostel C, Martin A, Alvaro V, Jaffiol C, Joubert D (1997) Protein kinase C alpha and tumorigenesis of the endocrine gland. Horm Res 47:140–144PubMedGoogle Scholar
  439. Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78:1337–1341PubMedGoogle Scholar
  440. Rahmsdorf HJ, Herrlich P (1990) Regulation of gene expression by tumor promoters. Pharmac Ther 48:157–188Google Scholar
  441. Rajotte D, Haddad P, Haman A, Cragoe EJJr, Hoang T (1992) Role of protein kinase C and the Na+/H+ antiporter in suppression of apoptosis by granulocyte macrophage colony-stimulating factor and interleukin-3. J Biol Chem 267:9980–9987PubMedGoogle Scholar
  442. Rea D, Prendiville J, Harris AL, Woll P, Phillip P, Carmichael J, Lewis C, Dallma M, Walker T, Sri-Pathmanathan E, Thatcher N, Crowther D (1992) A phase I study of bryostatin 1—a PKC partial agonist. Ann Ancol 3:62Google Scholar
  443. Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng C-P, Zou J, Oberley TD, Verma AK (1999) Transgenic mice overexpressing protein kinase C δ in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetat, Cancer Res 49:5710–5718Google Scholar
  444. Regev R, Assaraf YG, Eytan GD (1999) Membrane fluidization by ehter, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 259:18–24PubMedGoogle Scholar
  445. Rennecke J, Rehberger PA, Fürstenberger G, Johannes FJ, Stöhr M, Marks F, Richter KH (1999) Protein-kinase-Cμ expression correlates with enhanced kerationcate proliferation in normal and neoplastic mouse epidermis and in cell culture. Int J Cancer 80:98–103PubMedGoogle Scholar
  446. Riley RJ, Workman P (1992) DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43:1657–1669PubMedGoogle Scholar
  447. Robert J, Larsen AK (1998) Drug resistance to topoisomerase II inhibitors. Biochimie 80:247–254PubMedGoogle Scholar
  448. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD (1997) Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36:11169–11178PubMedGoogle Scholar
  449. Rodriguez-Pena A, Rozengurt E (1984) Disapperance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treatet 3T3 cells. Biochem Biophys Res Comm 120:1053–1059PubMedGoogle Scholar
  450. Romanova LY, Alexandrov IA, Schwab G, Hilbert DM, Mushinski JF, Nordan RP (1996) Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: role of PKC modulation and cell cycle. Biochemistry 35:9900–9906PubMedGoogle Scholar
  451. Rosales OR, Isales CM, Bhargava J (1998) Overexpression of protein kinase C alpha and betal has distinct effects on bovine aortic endothelial cell growth. Cell Signal 10:589–597PubMedGoogle Scholar
  452. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SPC, Doyle AL (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxanthrone-selected cell lines. J Natl Cancert Inst 91:429–433Google Scholar
  453. Ruiz-Ruiz MC, Izquierdo M, de Murcia G, Lopez-Rivas A (1997) Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Eur J Immunol 27:1442–1450PubMedGoogle Scholar
  454. Rusnak JM, Lazo JS (1996) Downregulation of protein kinase C suppresses induction of apoptosis in humanprostatic carcinoma cells. Exp Cell Res 224:189–99PubMedGoogle Scholar
  455. Ruvolo PP, Deng X, Carr BK, May WS (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273:25436–25442PubMedGoogle Scholar
  456. Sachs CW, Safa AR, Harrison SD, Fine RL (1995) Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270: 26639–26648PubMedGoogle Scholar
  457. Sachs CW, Ballas LM, Mascarella SW, Safa AR, Lewin AH, Loomis C, Carroll FI, Bell RM, Fine RL (1996) Effects of sphingosine stereoisomers on P-glycoprotein phosphorylation and vinblastine accumulation in multidrug-resistant MCF-7 cells. Biochem Pharmacol 52:603–612PubMedGoogle Scholar
  458. Sakakura C, Sweeney EA, Shirahama T, Hakomori S, Igarashi Y (1996) Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation. FEBS Lett 379:177–180PubMedGoogle Scholar
  459. Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM (1991) Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64:809–814PubMedGoogle Scholar
  460. Sakurada K, Zheng B, Kuo JF (1992) Comparative effects of protein phosphatase inhibitors (okadaic acid and calyculin A) on human leukemia HL60, HL60/ADR and K562 cells. Biochem Biophys Res Commun 187:488–492PubMedGoogle Scholar
  461. Sampson E, Wolff CL, Abraham I (1993) Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett 68:7–14PubMedGoogle Scholar
  462. Sanchez V, Lucas M, Sanz A, Goberna R (1992) Decreased protein kinase C activity is associated with programmed cell death (apoptosis) in freshly isolated rat hepatocytes. Biosci Rep 12:199–206PubMedGoogle Scholar
  463. Sanchez-Margalet V, Lucas M, Solano F, Goberna R (1993) Sensitivity of insulin-secreting RIN m5F cells to undergoing apoptosis by the protein kinase C inhibitor staurosporine. Exp Cell Res 209:160–163PubMedGoogle Scholar
  464. Sanchez-Perez I, Perona R (1999) Lack of c-Jun activity increases survival to cisplatin. FEBS Lett 453:151–158PubMedGoogle Scholar
  465. Sanchez-Prieto R, Vargas JA, Carnero A, Marchetti E, Romero J, Durantez A, Lacal JC, Ramon-y-Cajal S (1995) Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. Int J Cancer 60:235–243PubMedGoogle Scholar
  466. Sato W, Yusa K, Naito M, Tsuruo T (1990) Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Comm 173:1252–1257PubMedGoogle Scholar
  467. Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S (1998) Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 42, Suppl:S54–59Google Scholar
  468. Saxon ML, Zhao X, Black JD (1994) Activation of protein kinase C isozymes is associated with post-mitotic events in intestinal epithelial cells in situ. J Cell Biol 126:747–763PubMedGoogle Scholar
  469. Scaglione-Sewell B, Abraham C, Bissonnette M, Skarosi SF, Hart J, Davidson NO, Wali RK, Davis BH, Sitrin M, Brasitus TA (1998) Decreased PKC-alpha expression increases cellular proliferation, decreases differentiation, and enhances the transformed phenotype of CaCo-2 cells. Cancer Res 58:1074–1081PubMedGoogle Scholar
  470. Scala S, Dickstein B, Regis J, Szallasi Z, Blumberg PM, Bates SE (1995) Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clinical Cancer Res 1:15851–1587Google Scholar
  471. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T (1991) Cisplatin resistance in human acancers. Pharmac Ther 52:385–406Google Scholar
  472. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578–582PubMedGoogle Scholar
  473. Schiemann U, Assert R, Moskopp D, Gellner R, Hengst K, Gullotta F, Domschke W, Pfeiffer A (1997) Analysis of a protein kinase C-alpha mutation in human pituitary tumours. J Endocrinol 153:131–137PubMedGoogle Scholar
  474. Schimke RT (1986) Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer 57:1912–1917PubMedGoogle Scholar
  475. Schlatterer K, Krauter G, Schlatterer B, Hecker E, Chandra P (1999) A novel protein (p10) induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and other hyperplasiogenic tumor-promoting and non-promoting agents in murine epidermis. Anticancer Res 19:397–404PubMedGoogle Scholar
  476. Schönwasser DC, Marais RM, Marshall CJ, Parker PJ (1998) Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotype. Mol Cell Biol 18:90–798Google Scholar
  477. Schwartz GK, Arkin H, Holland JF, Ohnuma T (1991) Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate. Cancer Res 51:55–61PubMedGoogle Scholar
  478. Schwartz GK, Haimovitz Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F Jr, Kelsen DP, Fuks Z, Albino AP (1995) Potentiation of apoptosis by treatment with the protein kinase C specific inhibitor safingol in mitomycin C treatment with the protein kinase C specific inhibitor safingol in mitomycin C treated gastric cancer cells. J Natl Cancer Inst 87:1394–1399PubMedGoogle Scholar
  479. Segal-Bendirdjian E, Jacquemin-Sablon A (1996) Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis. Bull Cancer 83:371–378PubMedGoogle Scholar
  480. Sewing A, Wiseman B, Lloyd AC, Land H (1997) High-intensity raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17:5588–5597PubMedGoogle Scholar
  481. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ (1993) Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53:2081–2086PubMedGoogle Scholar
  482. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville AE, Worland PJ (1994) Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 45:1207–1214PubMedGoogle Scholar
  483. Sha EC, Sha MC, Kaufmann SH (1996) Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)-hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro. Invest New Drugs 13:285–294PubMedGoogle Scholar
  484. Shao RG, Cao CX, Pommier Y (1997) Activation of PKC alpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells. J Biol Chem 272:31321–31325PubMedGoogle Scholar
  485. Shaposhnikova VV, Dobrovinskaya OR, Eidus LKh, Korystov YN (1994) Dependence of thymocyte apoptosis on protein kinase C and phospholipase A2. FEBS Lett 348:317–319PubMedGoogle Scholar
  486. Shen L, Glazer RI (1998) Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding-protein-3. Biochem Pharmacol 55:1711–1719PubMedGoogle Scholar
  487. Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T, Sone S (1996) Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology 53:494–504PubMedGoogle Scholar
  488. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H (1999) Relative level of expression of bax and bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 18:5703–5713PubMedGoogle Scholar
  489. Shirahama T, Sakakura C, Sweeney EA, Ozawa M, Takemoto N, Nishiyama K, Ohi Y, Igarashi Y (1997) Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-X(L) gene expression. FEBS Lett 407:97–100PubMedGoogle Scholar
  490. Shoji M, Raynor RL, Berdel WE, Vogler WR, Kuo JF (1988) Effects of thioetherphospholipid BM41440 on PKC and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells. Cancer Res 48:6669–6673PubMedGoogle Scholar
  491. Shoji M, Raynor RL, Fleer EA, Eibl H, Vogler WR, Kuo JF (1991) Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells. Lipids 26:145–149PubMedGoogle Scholar
  492. Siemann DW, Jiang JB, Ballas L, Janzen W (1993) Threo-dihydrosphingosine potentiates the in vivo antitumor efficacy of cisplatin and adriamycin. Proc Am Assoc Cancer Res 34:410, 2452Google Scholar
  493. Sklar MD, Prochownik EV (1991) Modulation of cisplatinum resistance in friend erythroleukemia cells by c-myc. Cancer Res 51:2118–2123PubMedGoogle Scholar
  494. Slapak CA, Daniel JC, Levy SB (1990) Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increase P-glycoprotein expression. Cancer Res 50:7895–7901PubMedGoogle Scholar
  495. Smith CD, Zilfou JT (1995) Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270:28145–28152PubMedGoogle Scholar
  496. Smith JB, Smith L, Pettit GR (1985) Bryostatins: potent new mitogens that mimic phorbol ester tumor promoters. Biochem. Biophys Res Commun 132:939–945PubMedGoogle Scholar
  497. Smyth MJ, Drasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95:7024–7029PubMedGoogle Scholar
  498. Solary E, Bertrand R, Kohn KW, Pommier Y (1993) Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81:1359–1368PubMedGoogle Scholar
  499. Sommers GM, Alfieri AA (1998) Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model. Cancer Invest 16:462–470PubMedGoogle Scholar
  500. Spitaler M, Utz I, Hilbe W, Hofmann J, Grunicke HH (1998) PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem Pharmacol 56:861–869PubMedGoogle Scholar
  501. Spitaler M, Wiesenhofer B, Biedermann V, Seppi T, Zimmermann J, Grunicke H, Hofmann J (1999) The involvement of protein kinase C isoenzymes α, ɛ and ζ on the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res 19:3969–3976PubMedGoogle Scholar
  502. Staats J, Marquardt D, Center MS (1990) Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein. J Biol Chem 265:4084–4090PubMedGoogle Scholar
  503. Stabel S, Parker PJ (1991) Protein kinase C. Pharmac Ther 41:71–95Google Scholar
  504. Stabel S (1994) Protein kinase C—an enzyme and its relatives. Sem Cancer Biol 5:277–284Google Scholar
  505. Staroselsky AN, Fan D, O'Brian CA, Bucana CD, Gupta KP, Fidler IJ (1990) Sitedependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin. Cancer Res 50:7775–7780PubMedGoogle Scholar
  506. StCroix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS (1996) Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2:1204–1210Google Scholar
  507. StCroix B, Kerbel RS (1997) Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9:549–556Google Scholar
  508. Stevens VL, Nimkar S, Jamison WC, Liotta DC, Merrill AJJr (1990) Characteristics of the growth inhibition and cytotoxicity of long-chain (sphingoid) bases for Chinese hamster ovary cells: evidence for an involvement of protein kinase C. Biochim Biophys Acta 1051:37–45PubMedGoogle Scholar
  509. Stone RM, Sariban E, Pettit GR, Kufe DW (1988) Bryostatin 1 activates PKC and induces monocytic differentiation of HL60 cells. Blood 72:208–213PubMedGoogle Scholar
  510. Stromskaya TP, Grigorian IA, Ossovskaya VS, Rybalkina EY, Chumakov PM, Kopnin BP (1995) Cell-specific effects of RAS oncogene and protein kinase C agonist TPA on P-glycoprotein function. FEBS Lett 368:373–376PubMedGoogle Scholar
  511. Suga K, Sugimoto I, Ito H, Hashimoto E (1998) Down-regulation of protein kinase C-alpha detected in human colorectal cancer. Biochem Mol Biol Int 44:523–528PubMedGoogle Scholar
  512. Sun XG, Rotenberg SA (1999) Overexpression of protein kinase Calpha in MCF-10A human breast cells engenders dramatic alterations in morphology, proliferation, and motility. Cell Growth Differ 10:343–352PubMedGoogle Scholar
  513. Susick, RL, Bozigian HP, Kreutzberg J, Adams LM, Weiler MS, Harrison SD, Kedderis LB (1993) Combination toxicology studies with the chemopotentiating agent SPC-100270 (a PKC inhibitor) and chemotherapeutic agents. Proc Am Assoc Cancer Res 34:410, 2444Google Scholar
  514. Sutherland RM (1988) Cell and environment interactions in tumor microregions: the multicell speroid model. Science 240:177–184PubMedGoogle Scholar
  515. Szallasi Z, Smith CB, Pettit GR, Blumberg PM (1994) Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem 269:2118–2124PubMedGoogle Scholar
  516. Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM (1996) The bryostatins inhibit growth of B10/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociationo f activities using 26-epi-bryostatin 1. Cancer Res 56(9):2105–11PubMedGoogle Scholar
  517. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F (1989) Staurosporine, a potent inhibitor of phospholipid/Ca2+-dependent protein kinase. Biochem Biophys Res. Commun 135:397–402Google Scholar
  518. Teofili L, Pierelli L, Iovino MS, Leone G, Scambia G, De Vincenzo R, Benedetti-Panici P, Menichella G, Macri E, Piantelli M, Ranelletti FO, Larocca LM (1992) The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leuk Res 16:497–503PubMedGoogle Scholar
  519. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313–4320PubMedGoogle Scholar
  520. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissing P, Boursier E, Loriolle F, Duhamel L, Charon F, Kirilovski J (1991) The bis-indolylmaleimide GF109203x is a potent and selective inhibitor of PKC. J Biol Chem 266:15771–15781PubMedGoogle Scholar
  521. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP (1996) Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56:206–209PubMedGoogle Scholar
  522. Überall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51:807–812PubMedGoogle Scholar
  523. Überall F, Hellbert K, Kampfer S, Maly K, Villunger A, Spitaler M, Mwanjewe J, Baier-Bitterlich G, Baier G, Grunicke HH (1999) Evidence that atypical protein kinase C-λ and atypical protein kinase C-ζ participate in ras-mediated reorganization of the F-actin cytoskeleton. J Cell Biol 144:413–425PubMedGoogle Scholar
  524. Uchiumi T, Kohno K, Tanimura H, Hidaka K, Asakuno K, Abe H, Uchida Y, Kuwano M (1993) Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett 326:11–16PubMedGoogle Scholar
  525. Urasaki Y, Ueda T, Yoshida A, Fukushima T, Takeuchi N, Tsuruo T, Nakamura T (1996) Establishment of a daunorubicin-resistant cell line which shows multidrug resistance by multifactorial mechanisms. Anticancer Res 16:709–714PubMedGoogle Scholar
  526. Utz I, Hofer S, Regenass U, Hilbe W, Thaler J, Grunicke H, Hofmann J (1994) The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer 57:104–110PubMedGoogle Scholar
  527. Utz I, Gekeler V, Ise W, Beck J, Spitaler M, Grunicke H, Hofmann J (1996) Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutahione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Anticancer Res 16:289–296PubMedGoogle Scholar
  528. Utz I, Spitaler M, Rybczynska M, Ludescher C, Hilbe W, Regenass U, Grunicke H, Hofmann J (1998) Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int J Cancer 77:64–69PubMedGoogle Scholar
  529. Valverde AM, Sinnett-Smith J, Van Lint J, Rozengurt E (1994) Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc Natl Acad Sci USA 91:8572–8576PubMedGoogle Scholar
  530. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Oncol 16:56–62Google Scholar
  531. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465PubMedGoogle Scholar
  532. Vogler WR, Whigham E, Bennet WD, Olson AC (1995) Effect of alkyllysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines. Exp Hematol 13:629–633Google Scholar
  533. Volm M, Pommerenke EW (1995) Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res 15:463–466PubMedGoogle Scholar
  534. Wakusawa S, Nakamura S, Tajima K, Miyamoto K, Hagiwara M, Hidaka H (1992) Overcoming of vinblastine resistance by isoquinolinesulfonamide, compounds in adriamycin-resistant leukemia cells. Mol Pharmacol 41:1034–1038PubMedGoogle Scholar
  535. Wakusawa S, Inoko K, Miyamoto K (1993) Staurosporine derivatives reverse multidrug resistance without correlation with their protein kinase inhibitory activities. J Antibiotcs 46:335–337Google Scholar
  536. Walter RJ, Shtil AA, Roninson IB, Holian O (1997) 60-Hz electric fields inhibit protein kinase C activity and multidrug resistance gene (MDR1) up-regulation. Radiat Res 147:369–375PubMedGoogle Scholar
  537. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927–936PubMedGoogle Scholar
  538. Wang J, Walsh K (1996) Resistance to apoptosis conferred by CDK inhibitors during myocyte differentiation. Science 273:359–361.PubMedGoogle Scholar
  539. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM (1996) UCN-01: a potent abrogator of G1 checkpoint function in cancer cells with disrupted P53. J Natl Cancer Inst 88:956–965PubMedGoogle Scholar
  540. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S (1997) Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 52:1000–1009PubMedGoogle Scholar
  541. Wang XY, Repasky E, Liu HT (1999a) Antisense inhibition of protein kinase C alpha reverses the transformed phenotype in human lung carcinoma cells. Exp Cell Res 250:253–263PubMedGoogle Scholar
  542. Wang CY, Cusack JCJr, Liu R, Baldwin ASJr (1999b) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5:412–417PubMedGoogle Scholar
  543. Ward NE, O'Brian CA (1991) Distinct patterns of phorbol ester-induced downregulation of protein kinase C activity in adriamy cin-selected multidrug resistant and parental murine fibrosarcoma cells. Cancer Lett 58:189–193.PubMedGoogle Scholar
  544. Warenius HM, Seabra LA, Maw P (1986) Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not craf-1 protein. Int J Cancer 67: 224–231Google Scholar
  545. Watanabe T, Ono Y, Taniyama Y, Hazama K, Igarashi K, Ogita K, Kikkawa U, Nishizuka Y (1992) Cell division, arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-delta subspecies. Proc Natl Acad Sci USA 89:10159–10163PubMedGoogle Scholar
  546. Watts JD, Aebersold R, Polverino AJ, Patterson SD, Gu M (1999) Ceramide second messengers and ceramide assays. Trends Biochem Sci 282:228Google Scholar
  547. Ways DK, Posekany K, deVente J, Garris T, Chen J, Hooker J, Qin W, Cook P, Fletcher D, Parker P (1994) Overexpression of protein kinase C zeta stimulates leukemic cell differentiation. Cell Growth Differ 5:1195–1203PubMedGoogle Scholar
  548. Ways KD, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ (1995) MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive phenotype. J Clin Invest 95:1906–1915PubMedGoogle Scholar
  549. Weinstein IB (1991) Nonmutagenic mechanisms in carcinogenesis: Role of protein kinase C in signal transduction and growth control Environmental Health Perspectives 93:175–179.PubMedGoogle Scholar
  550. Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA (1999) Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J Biol Chem 274:10877–10888PubMedGoogle Scholar
  551. Westmacott D, Bradshow D, Kumar MKH, Lewis EJ, Murray EJ, Nixon JS, Sedgwick AD (1991) Molecular basis of new approaches to the therapy of rheumatoid arthritis. Molecular Aspects Med 12, 395–473Google Scholar
  552. Westphal CH, Hoyes KP, Canman CE, Huang X, Kastan MB, Hendry JH, Leder P (1998) Loss of ATM radiosensitizes multiple p53 null tissues. Cancer Res 58:5637–5639PubMedGoogle Scholar
  553. Whelan RD, Parker PJ (1998) Oncogene Loss of protein kinase C function induces an apoptotic response. Oncogene 16:1939–1944PubMedGoogle Scholar
  554. Whelan RD, Kiley SC, Parker PJ (1999) Tetradecanoyl phorbol acetate-induced microtubule reorganization is required for sustained mitogen-activated protein kinase activation and morphological differentiation of U937 cells. Cell Growth Diff 10:271–277PubMedGoogle Scholar
  555. White E, Prives C (1999) DNA damage enables p73. Natur 399:734–737Google Scholar
  556. Whitman SP, Civoli F, Daniel LW (1997) Protein kinase CbetaII activation by 1-beta-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl2alpha down-regulation. J Biol Chem 272:23481–2384PubMedGoogle Scholar
  557. Wielinga PR, Heijn M, Broxterman HJ, Lankelma J (1997) P-glycoproteinindependent decrease in drug accumulation by phorbol ester treatment of tumor cells. Biochem Pharmacol 54:791–799PubMedGoogle Scholar
  558. Williams AC, Collard TJ, Paraskeva C (1999) An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 18:3199–3204PubMedGoogle Scholar
  559. Wilson RE, Dooley TP, Hart IR (1989) Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. Cancer Res 49:711–716PubMedGoogle Scholar
  560. Woo KR, Shu WP, Kong L, Liu BC (1996) Tumor necrosis factor mediates apoptosis via Ca++/Mg++ dependent endonuclease with protein kinase C as a possible mechanism for cytokine resistance in human renal carcinoma cells. J Urol 155:1779–1783PubMedGoogle Scholar
  561. Woodley SL, McMillan M, Shelby J, Lynch DH, Roberts LK, Ensley RD, Barry WH (1991) Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation 83:1410–1418PubMedGoogle Scholar
  562. Wooten MW, Zhou G, Seibenhener ML, Coleman ES (1994) A role for zeta protein kinase C in nerve, growth factor-induced differentiation of PC12 cells. Cell Growth Differ 5:395–403PubMedGoogle Scholar
  563. Workman P (1991) Antitumor ether lipids: endocytosis as a determinant of cellular sensitivity. Cancer Cells 3:415–317Google Scholar
  564. Xiao H, Goldthwait DA, Mapstone T (1994) The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta. J Neurosurg 81:734–740PubMedGoogle Scholar
  565. Xu X, Baltimore D (1996) Dual roles of ATM in the cellular response to radiation and in cell growth. Gene Develop 10:2401–2410Google Scholar
  566. Yang JM, Chin KV, Hait WN (1996) Interaction of P-glycoprotein with protein kinase C in human multidrug resistant, carcinoma cells. Cancer Res 56:3490–3494PubMedGoogle Scholar
  567. Yarbro JW (1992) The scientific basis of cancer chemotherapy. In: The Chemotherapy Sourcebook (Perry MC ed.) Williams, Wilkins, 2–8Google Scholar
  568. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI (1996) Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothiate oligodeoxynucleotide. Mol Pharmacol 50:236–242PubMedGoogle Scholar
  569. Yen Y, Grill SP, Dutschman GE, Chang C-N, Zhou BS, Cheng Y-C (1984) Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 54:3686–3691Google Scholar
  570. Yoshida M, Feng W, Saijo N, Ikekawa T (1996) Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L. Int J Cancer 66:268–273PubMedGoogle Scholar
  571. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K Tsuruo T, Cowan KH, Glazer RI (1991) Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3:181–189PubMedGoogle Scholar
  572. Yu CW, Chen JH, Lin LY (1997) Metal-induced metallothionein gene expression can be inactivated by protein kinase C inhinbitor. FEBS Lett 420:69–73PubMedGoogle Scholar
  573. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H, O'Connor PM (1998) UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the WeelHu kinase and activation of the Cdc25C phosphatase. J Biol Chem 273:33455–33464PubMedGoogle Scholar
  574. Yuspa SH (1998) The pathogenesis of squamous cell cancer: lessions learned from studies of skin carcinogenesis. J Dermatol Sci 17:1–7PubMedGoogle Scholar
  575. Zellner A, Fetell MR, Bruce JN, De Vivo DC, O'Driscoll KR (1998) Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications. Clin Cancer Res 4:1797–1802PubMedGoogle Scholar
  576. Zhang W, Yamada H, Sakai N, Nozawa Y (1993) Sensitization of C6 glioma cells to radiation by staurosporine, a potent protein kinase C inhibitor. J Neurooncol 15:1–7PubMedGoogle Scholar
  577. Zheng B, Chambers TC, Raynor RL, Markham PN, Gebel HM, Vogler WR, Kuo JF (1994) Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C epsilon, exhibits multidrug resistance phenotype, and expresses drug pump p-glycoprotein. J Biol Chem 269:12332–12338PubMedGoogle Scholar
  578. Zhou T, Song L, Yang P, Wang Z, Lui D Jope RS (1999) Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nature Med 5:42–48PubMedGoogle Scholar
  579. Zhuang S, Lynch MC, Kochevar IE (1998) Activation of protein kinase C is required for protection of cells against apoptosis induced by singlet oxygen. FEBS Lett 437:158–162PubMedGoogle Scholar
  580. Ziegler WH, Parekh DB, Le Good JA, Whelan RD, Kelly JJ, Frech M, Hemmings BA, Parker PJ (1999) Rapamycin-sensitive phosphorylation of PKC on a carboxyterminal site by an atypical PKC complex. Curr Biol 9:522–529PubMedGoogle Scholar
  581. Zimmermann J, Caravatti G, Mett H, Meyer T, Muller M, Lydon NB, Fabbro D (1996) Phenylamino-pyramidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm 329:371–376Google Scholar
  582. Zini N, Neri LM, Ognibene A, Scottlandi K, Baldini N, Maraldi NM (1997) Increase of nuclear phosphatidylinositol 4,5-bisphosphate and phospholipase C beta 1 is not associated to variations of protein kinase C in multidrug-resistant Saos-2 cells. Microsc Res Tech 36:172–178PubMedGoogle Scholar
  583. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R, Arcamone F (1997) Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther 76:177–185PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin 2001

Authors and Affiliations

  • J. Hofmann
    • 1
  1. 1.Institute of Medical Chemistry and BiochemistryUniversity of InnsbruckInnsbruckAustria

Personalised recommendations